An Essay on Various Solutions to Weight Control Problems: Metabolic Normalization through Eleotin Products:

Table of Contents
Introduction

Chapter 1: Basic Understanding
What is Obesity?
Diagnosis ?Body Fat Ratio
Causes of Obesity: Disturbed Metabolism and Vicious Cycles
Six Factors of the Vicious Cycle of Obesity
Who Suffers from Obesity?
What are Sensible Weight Control Methods?
Obesity and Diabetes: Siamese Twins

Chapter 2: Consequences of Obesity
Complications and Related Diseases
Obesity’s Affect on Social and Sexual Life
The Vicious Cycle of Obesity

Chapter 3: Currently Available Weight Control Methods
Fasting
Selective Diet
Medication (pills and drugs)
Herbal Products and Dietary Supplements
Weight Loss Machines
Surgical Procedures
Criteria for Judging Sensible Weight Control Methods

Chapter 4: A Sensible Combination of Four Weight Control Methods
Stress Management
Sensible Eating Habits
Sensible Exercise
Metabolism Boosting Dietary Supplement

Chapter 5: Eleotin-Mb A Dietary Supplement for Basic Metabolism
How was Eleotin-Mb Developed?
How does Eleotin-Mb Work?
What Happens when Underweight People take Eleotin-Mb?
Weight Recovery
Is Eleotin-Mb Safe?
Any Side Effects or Drug Interactions?
How do you Prepare and Take Eleotin-Mb?
Balanced Eating Habits
Can Alcohol be Consumed with Eleotin-Mb?
Does the Body Develop any Resistance to Eleotin-Mb?
How long Should I Take Eleotin-Mb Before the Effects Start?
Eleotin-Mb and Diabetes
Improved Sexual Energy
Improvement of Sleeping Quality
Why is it Named Eleotin-Mb?
Eleotin-Mb Evaluated Against the Criteria for Judging a Sensible Weight Control Method
Additional information

Appendices
Appendix 1. Comparison of Current Weight Control Methods
Appendix 2. Eleotin-Mb Weight Control Effects (1)
Appendix 3. Eleotin-Mb Weight Control Effects (2)
Appendix 4. Mechanisms of Action of Eleotin-Mb

Introduction

More and more people are becoming concerned about their weight. Looking at recent obesity trends, they should be. More than half of North American adults are considered overweight today, and obesity analysts believe that the clear majority of Americans will become overweight within the next ten years. In other parts of the world, obesity is growing at a less alarming rate but is still prevalent. Worldwide, medical experts are now strongly warning their patients that obesity is a leading contributor to numerous long-term health threats. How can we slow or stop the progress of this alarming trend?

Of course, there are many weight control methods. Some methods appear to be quite innovative. There are programs like the diet cafe, diet package tours, fasting clinics, vegetable enzyme diet, one fruit diet, emperor’s diet, the protein diet etc. Yet, obesity is still spreading rampantly. The emergence of all of the above novel weight control methods is really just a sign of our frustration and willingness to try anything, rather than of the effectiveness of those methods.

Since society places such a huge premium on physical appearance, the demand for weight control products is enormous. The Weight Loss Industry understands that people are very desperate for a weight control product they can believe in. So numerous innovative products are introduced each year. Many people try these new products and spend billions of dollars each year. However, few people succeed at losing weight and those who so succeed initially tend to gain back the weight rapidly. These 뱘o-yo?customers are highly regarded by the Weight Loss Industry because they become repeat customers.

Isn’t it time we question why all these weight control methods always fail to deliver their promises? We need to discover what went fundamentally wrong. We need to understand what our realistic weight loss options are and the chances of achieving them. We believe that presently most people take a very simplistic approach that focuses only on how many pounds of weight they lose. As long as everyone focuses on the poundage lost, there is no way to solve the obesity problem. We must look deeper into how someone both gains and losses weight. Then we will be closer to the answer.

We believe that what we should not be very concerned about how many pounds are lost. Rather, we should focus on correcting the imbalance of the basic nutritional and energy metabolism that started the whole weight gain problem in the first place. We believe that focusing only on lost poundage is wrong and even dangerous. This narrow focus can often lead to using superficial weight loss approaches with many dangerous side effects, with only temporary weight loss results, and with an unrealistic chance of success.

We wrote this booklet to remove the many misconceptions and misunderstandings regarding weight control. Inside, the pros and cons of various weight control methods are compared and presented as objectively as possible. Also, we provide some basic scientific principles of how weight gain occurs and how to lose and control weight. Lastly, this book introduces information about a newly developed product called Eleotin-Mb, which has recently became popular in North America and Japan.

Chapter 1: Basic Understanding

What is Obesity?

Obesity is a state of being overweight, or having excessive fat. In medical terms, obesity is defined as having excess adipose (animal fat) tissue deposits. Alternatively, obesity means that the weight ratio of fat to total body mass exceeds 25% for men or 30% for women. On average, the normal ratio is around 18%.

Does a lower fat ratio mean a healthier, better body? While for most people this is true, the answer is not always yes. To keep a healthy body, we must maintain a certain fat level. Maintaining an excessively low fat ratio is not healthy. A normal and healthy fat ratio is around 18%. The human body largely consists of bones, muscles, and fat. The bones and muscles play the role of sustaining the body structure and its daily activities. Fat’s primary role is to store excess energy for use on a rainy day. Fat also constitutes an important part of our vital organs. Our brains, for example, is composed mostly of fat. When we are sick and the proper level of energy and nutrition is not supplied, body-fat begins to get disintegrated, becoming an alternative source of energy and nutrition. Therefore, when the fat ratio is too low, our body is exposed to the danger of not having enough reserve energy during a period of insufficient calorie intake (e.g. serious illness). Also, an insufficient fat supply hinders the formation of certain vital organs. The fat is usually 3%-5% of your total body weight. Fat is an important building material for many other key organs of the body. This is why simplistic fasting and extreme dieting often harm our body permanently. Body-fat itself is not harmful. Excess body-fat is harmful but insufficient body fat is equally harmful.

Diagnosis ?Body Fat Ratio

Men and women are considered obese when their body fat exceeds 25% or 30% respectively. However, measuring a person’s exact body fat ratio is not as easy stepping on some scale. So, for convenience, people can use the following methods:

1) Standard Weight Index: Normally, the standard weight is computed as (height in centimeters – 100cm) times 0.9. For example, for a person who stands 170cm, the above calculation is (170-100) * 0.9 = 63kg. Therefore, 63kg is the standard weight for a person whose height is 170 cm. If a person’s actual weight exceeds the standard weight by more than 20%, he is considered overweight. Degree 1 obesity is weighing 20% more than the standard weight. For the person above whose standard weight was 63 kg, he is Degree 1 obese if his weight is more than 75.6kg. For Degree 2 obesity, he should weigh more than 81.9kg, which is 30% over standard. Degree 3 obesity is 40% higher than the standard weight and Degree 4 obesity is 50% higher and so on. This method is relatively easy to use. But, this method does not really distinguish between a sturdy physique and someone who is overweight. In other words, according to this method, a highly trained body builder is equally classified with someone who is more overweight.

2) Body Mass Index: The body mass index is a ratio of one’s weight in kg to the square of your height in meters. For example, a person with a height of 170cm and a weight of 65kg, the body mass index calculation goes like 65kg/1.7m*1.7m=22.49. For this person, 22.49 is their body-mass number. Experts use the index to classify people. People with a body-mass number of 20-25 are considered normal, those between 25-29.9 are overweight, and those over 30 are labeled as obese. This is again a relatively simple method, it has the same weakness as the above standard weight index.

3) Skin Pinching Test: This method uses a compass-like skin-fold measurer to measure the skin-folds of the biceps and triceps. When used on triceps, obesity is defined as skin folds of more than 3cm for women and 2cm for men. This is a reasonably accurate test that should be available through you physician.

It is true that for most people determining who is fat and who is not fat is a relatively straightforward task. Therefore, for most of us, we do not need such sophisticated methods as described above. But, remember there may be some psychological dimensions to the obesity problem. For example, some overweight individuals can deny their problem. They maintain they are not 몋hat?overweight. For these people, and for everyone else who enjoys calculating some weight ratio numbers, we hope you like the above calculations. But, for the rest of us, these calculations are just academic since we already know our weight situation.

Causes of Obesity: Disturbed Metabolism and Vicious Cycles

Obesity starts when something goes wrong with our basic nutrition and energy metabolism. Through our basic metabolism, nutrients are taken in, digested and transformed into energy to fuel our activities and maintain basic biological functions such as breathing. Carbohydrates that are consumed are digested and turned into blood sugar, which is the fuel for human activities and basic biological sustenance. Healthy people maintain a balance between the nutrition intake (the fuel) and its usage (cellular burning of the fuel). As long as there is a healthy balance in this basic metabolism, one does not become overweight.

However, once something goes wrong your basic metabolism, the vicious cycle of obesity gradually sets in. Here is an example of the typical stages of damage that occurs to a person’s basic metabolism:

Stage 1 – Constant overeating leads to high blood sugar levels and over time the unused blood sugar is converted into body fat. At the same time, high blood sugar levels require the body to produce larger quantities of insulin to process the high blood sugar. Insulin is a hormone that helps transfer the blood sugar from the blood system to the body’s cells.

Stage 2 – After several years, the body’s ability to produce insulin has diminished considerably. During this time the body also reacts very negatively to the prior excessive production of insulin and the body begins to use insulin less efficiently. Thus after several years of high blood sugar, insulin production becomes weak and your body also becomes resistant toward the insulin it produces. Once, the insulin balance is disturbed like this, the body has one fewer weapon to fight against obesity.

Stage 3 ?Numerous years of this vicious cycle of obesity can lead to numerous medical complications with diabetes and heart disease being the most common.

To summarize the vicious cycle can be seen as 1) Habitual overeating that leads to 2) high blood sugar and long term high blood sugar which leads to 3) insulin insufficiency and insulin resistance. Insulin insufficiency and insulin resistance leads to diabetes 4) diabetes and other major complication that lead to a still higher blood sugar levels.

In fact, there are several dimensions of this vicious cycle of obesity. In the above example, even though the individual is overeating, the person’s cells may still receive insufficient fuel (blood sugar). How can this happen? Since insufficient insulin was released, the excessive blood sugar of the overeater remains in their blood stream. Therefore, their cells cry to the brain for more energy/nutrition. The brain interprets this signal as a demand for more food and the individual will feel a need to eat more. Additional overeating starts another cycle.

In sum, in the vicious cycle of obesity, eating more leads to eating still more through a few well-known mechanisms. As long as the disturbed basic metabolism stays unfixed, the basic energy metabolism tends to get worse and worse. Somehow, one must cut this vicious cycle, and rehabilitate the body뭩 basic metabolism. Remember, the quicker you stop this vicious obesity cycle the better. Prevention is always preferred. In order to prevent obesity, one has to be aware of those factors which lead to obesity.

Six Factors of the Vicious Cycle of Obesity

There seem to be about six factors that start the above mentioned vicious obesity cycle:

1. Poor Eating Habits – Overeating obviously starts and aggravates obesity. This does not require too much explanation. Just look around. Modern men and women simply eat too much and too often. However, it is no only quantity of the food consumed but also the quality. It is noteworthy, that the lack of some important nutrients also leads to obesity. Partial malnutrition leads to obesity too. When certain nutrients are insufficient due to an unbalanced diet, our body continuously demands those insufficient nutrients, and more often than not this leads to additional overeating. You would be surprised to find out how unbalanced a fast-food meal is or how few nutrients are contained in all junk food. If one relies on junk food for even 15% of your food consumption, it can lead to serious obesity and malnutrition at the same time.

2. Environmental Factors ?Our way of living is constantly changing, new environmental changes are introduced daily. For example, Chinese people used to drink a lot of tea. Tea, in general is extremely healthy, and contains some very important nutrients. Now, soft drinks like Coke-Cola have saturated the Chinese market and are massively consumed. It is no wonder that the obesity problem in China has increased. Another simple example would be more automobiles lead to more obesity. Also, we believe that more computers will lead to more people spending their time in front of a screen rather than moving around. More obesity will definitely result from more computers. If we look around, whenever there is a change in our life style toward more convenience, it almost always leads to more obesity. This is a tragic price we have to pay for modernity.

3. Drug Side Effects – Medications like birth control pills, antihistamine medications, asthmatic and allergy pills may also be a cause to obesity. These drugs are quite frequently used. Therefore, most of us have been exposed to the danger of obesity from the side effects of these drugs. As a principle, any drug that causes a change in your hormone balance tends to lead to obesity. We should know that gaining weight is one of the most common side effects of all the drugs. Some herbal products also have weight gain side effects because they stimulate appetite. We tend to underestimate the seriousness of obesity related drug side effects. The obesity caused by drug side effects is harder to handle than the obesity caused by other factors. Thus, we have to pay extra attention to the drug side effects related to obesity .

4. Genetic Factors – When parents are overweight, the chance of children being overweight is as high as 50-70%. When parents are overweight, children should be very careful. Recently, scientists have claimed to have found the 밼at genes? In theory, this is fantastic. Wouldn’t it be fashionable to blame everything on certain 밼at genes? This would be great because then no one has to feel guilty and the solution sounds simple to fix. Although promising, it will take numerous years until a miracle gene therapy safely blocks the culprit fat genes.

5. Psychological Factors ?Stress can cause people to overeat. Such compulsive eating surely contributes to a person뭩 obesity. Also, stress adversely affects the hormonal balance and becomes a contributing factor to obesity. Other, more serious psychological problems like depression can also lead to overeating. If this is an important factor in your situation, we recommend that you seek expert guidance to ensure that this factor is minimized.

6. Hormone Disorders – As was just mentioned, any hormone disorder can cause obesity. Some argue, quite controversially, that hormone disorders are very rare and only apply to 1% of obesity patients. As pregnancy hormonal problems can lead to large permanent weight gain, we do not agree with this assessment. However, as not much is known about this cause, we are unable to substantiate this belief.

Who Suffers from Obesity?

In affluent countries, obesity is more prevalent. Of course, in North America, the obesity problem is very serious. In Canada, 30.5% of the total population suffer from weight problems. The above figure when further segregated is more startling. Over 50% of all adults in Canada are considered overweight. The situation is no better in the U.S. In 1996, there were also more overweight adults than normal adults. In 1996, there was an estimated 70 million people who were overweight. Due to the steep growth rate and pervasive effect on all age categories, U.S. obesity forecasts are very pessimistic. Some forecasts indicate that within 20 years, a clear majority of all Americans (65%) will be overweight if nothing is done. Nobody, it seems, is safe from the threat of obesity.

What are Sensible Weight Control Methods?

It is important that 몏eight control?methods should be sensible. Weight control methods should be about more than simple weight loss. They should focus on a method to normalize the person’s metabolic balance, and as a result they should provide weight loss. Weight loss at any cost is a wrong approach and always very dangerous. Let’s take the example of a glamorous weight control method called 멿iposuction? This is an extreme weight control method that works by directly removing body fat out of a person’s body through a surgical operation. Of course, the immediate consequence of this surgery is that your body weight is declined, and your body fat ratio is reduced. However, there are very serious side effects from this operation and the initial weight loss tends to return very quickly. This surgical operation does not address the fundamental causes of weight gain it simply an quick way for individuals to experience a large loss in weight. Of course, the fat comes back quickly. In order for a weight control method to have real and long lasting benefits, that weight control method should contribute toward the normalization of the basic nutrition and energy metabolism. There is no other way. Basic nutrition and energy metabolism is where the problem started. Therefore, that is where the solution must be found.

Obesity and Diabetes: Siamese Twins

Diabetes and obesity are so closely related that many experts say that obesity and diabetes are like two sides of the same coin. That is, these experts feel that any discussion about obesity must include a discussion about diabetes because they are so similar. It is little wonder that many obesity specialists are also diabetes specialists. Let’s review their similarities. Diabetes results from a metabolic imbalance that is very similar to obesity. Diabetes is a disease that results from 1) Insulin not being produced or secreted properly, 2) an increase in insulin resistance. The outcome is high blood sugar, which will result in body fat increase. The second similarity is that diabetes and obesity are highly correlated. That is, 75% of all obese individuals also suffer from diabetes. Obesity can often trigger diabetes and diabetes can lead to obesity. Diabetic patients should be extra careful about their weight and obese individuals should take preventative steps due to their high likelihood of becoming diabetic. Diabetes disarms an individual of the weapons to fight obesity and obesity worsens diabetes. There are so many similarities between them that doctors refer to the two as Siamese Twins. Also, experts agree that if there are permanent solution to diabetes, it must be also permanent solution to obesity, and vice versa.

The discovery presented in this book, Eleotin-Mb, was originally based on diabetes treatment called P-700. The Julia Macfarlane Diabetes Research Center (the University of Calgary) developed the P-700 diabetes treatment. The P-700 treatment was shown to naturally and safely control blood glucose levels. After a six-month usage of P-700, diabetic complications were reduced and the reduction was maintained semi-permanently. This diabetes treatment technology has been licensed to Eastwood Bio-Medical Research Inc. since January 1998 under the brand name – Eleotin A, B, and C. When Eleotin was reported to the American Diabetes Association, one of the world’s leading diabetic scholars suggested to Eastwood that they should apply the Eleotin technology to develop a weight control product. His reasoning was that since Eleotin provided semi-permanent diabetes protection and control, it would also be successful at providing long lasting weight loss. As we explained earlier, diabetes and obesity are two sides of the same coin. The improvement and control of diabetes naturally requires weight loss if that is a contributing factor to the diabetes. Therefore, Eastwood began to review how the Eleotin technology could be amended and developed into an effective weight control product. Based on the recommendations of the American Diabetes Association and the University of Calgary, Eastwood completed its analysis and review and a new weight control technology has emerged. From the original diabetes treatment technology, Eleotin, primary hypoglycemic ingredients (blood sugar lowering ingredients) were removed, and metabolism-boosting ingredients were added. The result was the creation of Eleotin-Mb.

CHAPTER 2: Consequences of Obesity

Complications and Related Diseases

We are constantly told how bad obesity is. Well, let뭩 just repeat the reasons one more time.

Obesity is dangerous because it is directly and indirectly related to so many diseases.

1. Coronary Diseases – Experts say that obesity is one of the leading causes of heart disease. The fat deposits around the heart continue to burden the heart muscles forcing them to work harder. This additional workload increases the individual’s chance of various heart diseases. The fat deposits accumulated around the abdominal region also increase the likelihood of heart disease, as well as, diabetes. Excess fat accumulation in the veins and arteries imposes an obstacle for smooth blood-circulation. Severe capillary troubles are the eventual result as blood cells clogs and capillaries break. If this happens in the brain, it is called a stroke and it can result in permanent paralyses and death. Obese people have a 75% higher chance of suffering a stroke than other people.

2. Diabetes – We have already explained diabetes. So, let’s just say that the correlation between obesity and diabetes is so close that many experts regard these two as Siamese Twins. The correlation is approximately 75% of diabetic are also obese. Diabetes is called the disease of diseases?because it is a major contributor to so many other diseases. Diabetes can lead to blindness, kidney disease, heart disease, infections and amputations,. Obesity and diabetes make a lethal combination.

3. Liver Diseases – Obese people often develop fatty livers. Fatty livers can develop into liver cirrhosis the hardening of the liver. Also, these individuals more readily have gallstone problems. Medically this is called cholelithiasis. In other words, obesity can often develop into a fatal liver disease.

4. Pregnancy Related Disorders – Hormonal imbalance caused by obesity may bring about serious pregnancy related disorders. Also a woman’s pregnancy may cause a disruption her hormonal balance that leads to excessive weight gain during the pregnancy. These disorders are not difficult to understand intuitively if we consider how many hormones are intricately interrelated during the whole process of pregnancy. Obesity is never good however obesity becomes particularly harmful during pregnancy. Also, some women never regain their hormonal balance after pregnancy. They will find it extremely difficult to loss their additional pregnancy poundage.

5. Bones and Joints ?Being overweight will creates pain in the lower back, knees, and ankles. These organs are created to sustain only a certain amount of weight. Obviously, constant and excessive weight can cause problems in these joints. Experts believe that many forms of arthritis are caused or worsened by the person being overweight.

We could continue to provide more examples as there is a very long list of complications and diseases resulting from obesity. However, we believe you now fully understand our point on the grave danger of being overweight.

Obesity뭩 Affect on Social and Sexual Life

Even though beauty and attractiveness are quite a subjective matter, obesity can hardly be seen as an improvement to a person몊 appearance.

It may not be politically correct to state that being overweight is not attractive but that is why there is such a demand for weight loss products. Why do people feel less attractive when they are overweight? Some concrete physical reasons we will provided. Why do people easily lose their confidence if they feel they are overweight? There are many theories why our confidence is affected by how we perceive our physical appearance. Finally, why does being overweight seriously affect a person’s social and sexual life in so many ways? Regardless of the theories, the general consensus is that being overweight puts a large strain on our confidence and can lead to many behavior changes. These changes in thoughts and behavior impact our social and sexual lives.

People feel less attractive for many reasons. There are many physical reasons which will cause a person to feel unattractive. Obese people’s physique appears very soft and slouched down. Since fat sags, men’s chest and belly sinks down. Females suffer from the sagging in the lower abdominal, hips, and thighs. When fat is accumulated in the skin layer, it induces skin expansion. If skin is expanded beyond its capacity, skin rips. In areas where fat is easily accumulated such as, lower abdominal, hips, thighs, and calves the skin is most prone to rips first. It is wrong to think that only pregnant women have this skin-tearing problem. Many overweight men and women suffer even more.

Obese individuals also have a greater body odor problem. All areas where flesh meets flesh such as the groin, arm pits, and toes can start to smell. Air is not able to circulate in such areas and skin diseases such as eczema and athlete’s feet occur, leading to odor. The problem becomes more serious especially in the summer time. Sooner or later, obese people themselves become very conscious of this odor problem. Naturally, individuals suffering from the above physical consequences of obesity can begin to lose confidence in themselves. They develop a very negative self-image in themselves and it starts to dramatically affect their thoughts and behavior.

For example, let’s examine how obesity can affect teenagers. Teenagers who are very overweight develop oversized knees and ankles to support their weight. This leads to bad walking postures and unattractive physiques. Overtime they develop very negative self-images. Also their learning ability at school can be affected. When too much fat becomes stored in the blood system, blood circulation is aggravated. The poor blood circulation can cause drowsiness, fatigue, and the appearance of laziness. If the blood flow to the brain is also aggravated or slowed, the teenager’s memory capacity may start to weaken and concentration becomes more difficult. Naturally, many of these teenagers start to avoid or limit relationships with friends and their school life also suffers.

Many adults also suffer from serious social setbacks due to their obesity. Quite often they are discriminated in some manner at work because obesity is often regarded as a sign of laziness. This seems to raise the standard for obese individuals. They had better ensure their work rate does not fall or they will become labeled as non-productive. However, if their confidence level drops, they may begin avoiding social and business contacts with co-workers. They may feel less confident in their ability to handle their work stress. This in turn further aggravates other aspects of their life (home life or physical fitness). This is yet another possible loop in obesity’s vicious cycle. Obesity makes people lose confidence, they go out less, less become even less physically active, they eat more when depressed and, they become even more obese.

Obesity does not help a person’s sex life either. Fat accumulated in sexually sensitive spots usually reduces their sensitivity to stimulation. Consequently, obese people lose interest in sex. Also, their poor physical stamina is a further deterrent to their sex life. Since they are more likely to be tired, they are less interested in sex. Sometimes the individual’s sexual confidence is another deterring factor to sex. They are more conscious of how their partner may be reacting to their weight. Sometimes serious cases of fat deposits may even make intercourse itself impossible, as the sexual organs are planted too deeply in the flesh. Through these and other processes, obese people become more and more distanced from sex. Male impotency is very prevalent among obese males. Especially, for a male diabetic, almost 50% of them become sexually impotent within 5-7 years. Erections become impossible due to the capillaries being blocked and other nerve damage. Thus being overweight can have a profound effect on how both we and others view ourselves. This in turn, impacts on our on our social and sexual lives.

The Vicious Cycle of Obesity

Obesity does not heal itself. Once the underlying mechanisms of obesity start, they seem to continue and intensify unless something is done. For example, most statisticians understand the difficulty of impeding or correcting obesity when it begins. Thus the most important statistical factor to explain future obesity levels is previous obesity levels. They understand that obesity intensifies its hold, and that once obesity is in the system, it persists. We also realize that becoming older does not seem to improve our obesity. This is a large concern since the rate of obesity in children is growing at a dangerous pace. Left alone, obesity does not go away and it usually gets worse. Therefore we must be very concerned. It may start out as a very mild and simple thing. People may tell you, don’t worry, you are still OK? You yourself may want to believe it too. But, sooner or later, your condition becomes more severe and serious. That is why it is so dangerous.

There are a few loops through which obesity intensifies itself. Insulin resistance, appetite induced by partial malnutrition, activity aversion, etc. Something sensible and fundamental should be done to the basic energy metabolism. Otherwise, obesity can only get worse.

CHAPTER 3: Currently Available Weight Control Methods

Currently there are 6 groups of popular weight control methods:

1) Fasting
2) Selective diet
3) Medication
4) Herbal products
5) Machines
6) Surgical methods

Let us look closely at each one of them.

1) Fasting

There are two types of fasting. One is pure fasting where you do not eat or drink anything except for water for a certain period of time. The period ranges from one week to 15 days. The other fasting method is to take water, vitamins, and some minerals while excluding everything else. Partial fasting may include some foods. Anyhow, all types of fasting share the same idea of drastically reducing food intake.

Fasting reduces fat by about 1 lb. (500g) per day. We require quite a bit of energy just to maintain our body temperature and basic biological functions such as pulse and breathing. When there is no food intake, the body takes out the needed energy from the fat previously stored. Therefore, fasting may look like a very effective weight loss method if we just look at short-term weight reduction. However, it is not that simple. Fasting is very difficult and traumatic on your body. Also, fasting severely curtails your energy levels making it almost impossible to perform daily activities. The most serious side effect of fasting is it often destroys our normal energy metabolism. This destruction works as follows. When you begin to fast your body’s metabolism reacts by slowing down and trying to conserve the present fat storage. Even after fasting, your body’s basic metabolism does not return to normal for some time. Therefore, after a fast people tend to gain back all the weight lost at even a faster pace because their slow metabolism is not burning off the normal amount of calories. This process can be compared to people who have experienced financial difficulties. They begin to conserve their pennies and save more. Fasting is similar; the body becomes more efficient at saving calories to add on new fat deposits. Almost always the weight lost comes back very quickly. Most of the weight loss achieved during the fasting period comes back within two to three weeks even with normal eating. Remember the body is desperately trying to store energy since it has been fooled into believing there is a lack of food available for consumption. In most cases, obesity levels after fasting are more serious than pre fasting levels. The body’s basic metabolism has been altered and it is more prone to adding weight. The capacity to burn calories is severely damaged.

Due to the physical and mental strain of a fast, a serious fast may lead to a serious depression. This state of depression may cause individuals to overeat after fasting. Fasting may also cause permanent damage upon key organs due to the lack of nutrition consumed during the fast. Considering all these points, we do not recommend fasting as a suitable weight loss method.

2) Selective Diet

After fasting, the next weight control method is maintaining a selective diet. That is, eating smaller portions of select things. For example, if the daily intake of calories is reduced to 1000cal, weight can be reduced by 8-10kg in the first month and 15-20kg in the next three months. Two popular examples of this method is the 멖ollywood 18-day diet?and 멦he Scarsdale Medical Diet? Selective diets also include the one food diet. The one-food diets allow you to eat regular to plentiful amounts but only few kinds of food. A few common examples are the 멐mperor뭩 Diet?which allows you to eat only meat or the 밎rape Diet?where you can consume as many grapes as you like.

Selective diets should be evaluated using the same guidelines that we use to determine a healthy balanced diet. Thus selective diets are normally deficient in one of two ways. First they cause a disruption in our basic metabolic system, because like fasting they drastically reduce our food intake. The body’s reaction is always the same ?it slows our metabolism further. This causes future weight gain to be even larger. Second, these selective diets can cause a malnutrition problem because your diet is no longer properly balanced. Eating all the meat that you want may sound appealing to the dieter but it will cause a nutrition imbalance. The body뭩 cells will react to this nutrition imbalance by demanding further food. This will eventually lead to additional eating. We are not suggesting all these selective diets are harmful to you, however, please be careful. They can be very similar to fasting methods and leave permanent changes on your basic metabolism that will lead to long-term weight concerns.

3) Medication (pills and drugs)

Some people use drugs to control their weight. There are drugs which suppress appetite, drugs that act as diuretics, and drugs for many other purposes. When taking any drug you should always be concerned about side effects and dependency.

Here are a few of the most common drug groups that suppress a person뭩 appetite:

1) Catecholamine is sold under the brand names Phenthermine, Mazindol, Diethylpropion and Phenylpropanolamine. The Catecholamine drug group works by stimulating the 몊atisfaction?nerves in our brain or by numbing our 멲ppetite?nerves. As side effects, this drug group raises a person뭩 blood pressure and may cause an irregular pulse.

2) Serotonon is sold under the brand names DL-fenflurammine, Dexfenflurammine, Fluoxetine, or Fluvoxamine. The Serotonon drug group stimulates the secretion of Serotonin which increases the feeling of fullness. On the average, these drugs tend to decrease meal sizes by 15%. The side effects of this medication are sedation and low blood pressure.

3)PhenFen is also known to reduce appetite. It was very popular in the North America but it has now been shown to have serious side effects on the heart.

There are also drugs that act as diuretic agents to stimulate urination. Healthy urination is vital to the body because it secretes all kinds of accumulated wastes out of the system. Urination is the body뭩 cleansing system. Most medicinal herbs contain diuretic ingredients. Diuretics are often used to treat high blood pressure and swellings from high blood pressure and kidney diseases. Also, most diuretic agents are known to have some weight controlling effects. Some diuretic agents produce weight loss by reducing only the amount of water in the body, and some agents remove other things too. It is natural to consider diuretic agents as a method to control weight.

However, there are many kinds of diuretic agents. If too much or the wrong diuretic agents are taken, the body develops certain resistance toward the specific diuretic stimulation. Also, the body starts to depend on diuretic stimulation even for normal urination. Our bodies are known to develop resistance to all chemical diuretic agents. Also, chemical diuretic agents are known to have other serious side effects. Some key nutrients also go out of the body in the diuretic process, occasionally resulting in malnutrition. Therefore, we have to be careful before using diuretic agents for weight control. Weight loss that results from diuretics is mostly temporary water lose, anyway. Weight loss incurred by diuretic agents certainly comes back quickly. However, diuretic agents are very important and valuable tools for many purposes, but can not be relied upon as a means of safe and permanent weight control.

Recently, there have been a few popular drugs for weight loss. One of them is called Xenical, a drug marketed by Hoffmann-La Roche. Xenical has been a tremendous success of the pharmaceutical industry. It claims to be the first 몁on systemic lipase inhibitor? This means that it prevents the body from absorbing fat. This is a fantastic claim, but it is still a new product. We need more time to really evaluate this product. According to Dr. Morton Maxwell at UCLA뭩 Obesity Center, only one third of the users have seen positive effects. It is also expensive – $4-5 dollars for a day뭩 dosage. It can cause nausea. Xenical is a prescript-xion drug. We believe that once the body is accustomed to Xenical, the body will become dependent upon Xenical for handling fat. The body뭩 metabolism will also be reduced and the individual will become more obesity prone. As its known effects are still short term ones, we will have to continue to monitor this drug.

Cellasene is another recent commercial success. In some countries, it is not considered a drug and sold as a dietary supplement. It is made of a few herbs that have a well-known efficacy to help the circulation of the capillaries. One of these herbs is Ginko Biloba. It should be taken three times a day for eight weeks. After this it should be taken one time per day for maintenance. Cellasene claims to tighten up those lose fat parts on the hip and thigh areas. But, it does not control weight. It just tightens up those loose areas. The manufacturer stresses, 뱘ou may not lose weight, but you will lose inches? Some doctors who have used it say that it actually does make people lose inches in just four weeks. Side effects such as dry mouth have been reported. This product does not stress weight loss but instead becoming more compact or losing inches.

Well, you will hear about several new kinds of drug products every year. Some of them may be good while most usually have long term side effects. Later in this booklet, we explain some guidelines to determine which of these 몏onder drugs?and 몀iracle treatments?are truly sensible weight loss methods.

4) Herbal Products and Dietary Supplements

Recently, various Chinese herbal medicines have been introduced to western countries. Chinese herbal medicines claim to be different from western pharmaceutical drugs. They claim to work on the whole human body. Thus their goal is to improve a person뭩 general health while treating obesity. Many Chinese herbal medicines claim that they are free from side effects because they are made from natural plants.

We agree with the goals of Chinese herbal medicine. A person뭩 general metabolic condition must be improved if we are to properly treat obesity. This requires a whole body approach. However, we emphasize that all the claims of these Chinese herbal medicines should be reviewed carefully. For example, being 몁atural?itself does not guarantee safety. There are many natural substances that are quite dangerous. Also when a product is produced in China there is a concern about the lack of quality control. One should investigate 1) whether any herbs are contaminated by herbicides, pesticides or chemical fertilizers 2) whether the Chinese herbal medicine was manufactured under the correct environment and scientific controls and 3) whether the herbs listed are truly what is being provided. One extreme example is that a small percentage of Chinese medicinal herbs have been shown to contain traces of herbs such as Mahuang (Ephedra). Mahuang is known to be a strong narcotic.

Some Chinese herbal medicines used for weight control contain the aforementioned Mahuang and other herbs whose narcotic ingredients heighten metabolism. Increased metabolism stimulated by narcotic agents will surely lead to weight reduction. But, this is obviously not a healthy method of weight control.

Some countries put these herbal medicines on their black lists. The side effects can be quite severe, like causing permanent kidney and liver damage. It is wrong to believe that something is 몊afe?because people say that the product is 몁atural?

Another group of herbal products, which deserve comments are 몋hermogenic?products which are based on herbal extracts such as Guggulipid, Fucus, Cola Nut, and Ginger. The name 몋hermogenic?stands for the herb뭩 ability to raise body temperature. The way these herbal products work is by changing how the thyroid gland works. We have indicated already that changing the hormonal balance of a person in general may be dangerous. Even though this particular hormonal change was not yet extensively studied, changing how this thyroid functions may have very serious long-term side effects. The brand names of this 몋hermogenic뭛roup are Thyrolean, TLN, Natural Balance, Reduce 7 in 1, and Metabolean.

Other herbal products and dietary supplements have some weight control effects, simply because they block the digestion process. Some work because they induce diarrhea and others induce constipation. Some make food expand inside the stomach. Some claim that they assist the coagulation of fats and then these fats leave the body. All of these products have side effects. As long as these products fail to address the basic metabolic problem (the vicious cycle of obesity), these products effect will only be temporary. Temporary effects but your body may be exposed to several dangerous side effects.

5) Weight Loss Machines

Steam sauna boxes, motorized massage machines, electronic muscle stimulating machines, etc. are constantly being promoted on TV뭩 shopping channels. Again, fancy names are very common – the Fitsizers, Enercisers, Abbusters, Metabosizers are just a few. These products?promises are also common: ? minutes a day, will loss you 10 pounds a month? If these machines would actually build up your muscle mass then they might really burn off the fat they promised. The increased muscle cells will demand additional blood sugar fuel, this will reduce a person뭩 fat level as long as they maintain a steady diet.

However ? minutes a day?will never create enough new muscle mass to reduce ?0 pounds a month? Increasing your muscle mass does not happen this easily. Metabolism changes do not happen like that, either. Tummies do not go away in 5 minutes either. We do not wish to discourage anyone from exercising, even if it is just 5 minutes per day. Some of these products can be quite helpful. We recommend those machines which actually allow smooth and well regulated aerobic exercises (bike machines, treadmills, cross-country ski machines). Remember, as with all exercise programs, you must approach them in a positive and consistent manner. Or else, your exercise machines will only collect dust and become a worthless piece of equipment.

6) Surgical Procedures

We feel strongly that nothing positive can be said about surgical procedures. They can be extremely damaging to your body in the long run. In sum, they are also expensive, painful and permanently harmful. Having indicated our opinion, let뭩 describe briefly some of your surgical options:

1) Vertical Section of Stomach: This operation makes the stomach smaller by cutting the stomach vertically.

2) Stomach Stapling: The stomach and the upper intestines are stapled together to prevent the absorption of nutrients in the small intestines.

3) Jaw Wiring: This operation makes food intake more difficult by binding up the chin and allowing food intake only through a straw.

4) Liposuction: Suction of the body fat using a thin tube. Of the surgical methods, this is most popular because in theory the problematic fat areas can be removed separately and instantly.

Once again, our biggest problem with these surgical procedures is they do not address the metabolic problem. Stapling and making the stomach smaller is a very harsh reaction to stopping overeating. So is jar wiring. Over time the stomach expands as the body craves more fuel and nutrients as it is being staved by this restrictive diet. The surgeons understand this but hope that the person loses a great deal of weight in the initial weeks. We have already described how dangerous liposuction can be. These surgical methods should be used only for extreme cases.

Criteria for Judging Sensible Weight Control Methods

As the obesity problem is a global problem, we will hear about many novel weight control methods. We must always be in a position to know how to evaluate these methods. In this section, we introduce a few criteria to properly evaluate these methods.

We should not chose a weight control method by looking at just one criteria ?weight loss. We must be informed and evaluate all methods by several key criteria. The true objective of weight control is recovering a healthy body metabolism as this will lead to weight loss and looking and feeling better. Weight loss is just a measurement one small indicator of how we are progressing toward this objective. If we keep this in perspective, then it is possible to make the right weight loss choice. Generally, a sensible weight control method should meet the following seven requirements.

1) Whole Body Approach ?The method should be effective on the whole body, as opposed to concentrating on only a few parts. In other words, if some methods promise that certain parts of our body only will be affected, we should be more skeptical. Side effects are more likely as the method focuses on one region. Obesity is a problem that effects a person뭩 whole body and so the solution must address the whole body. If it only addresses a certain area of the body you should expect a limited or temporary weight loss effect.

2) Basic Metabolic Normalization – They should improve and normalize the body뭩 overall basic metabolism. This is the central theme of this booklet. Otherwise, the method is considered cosmetic or plain harmful to the long-term health of the individual.

3) Pain & Effect on Outlook ?The method should be low in pain. There is no reason why for most people this problem needs to be treated in a manner that involves a great deal of pain. The Method should not cause depression or have a large negative effect on the person뭩 outlook.

4) Lack of Side Effects – There should be no side effects. The method should be safe. Toxicity and other contaminants like herbicides, insecticides and chemical fertilizers should be monitored closely. Remember even if it is a natural product it may not be safe.

5) No Resistance or Dependence ?The method should not cause either resistance or dependence to be developed. We should avoid all methods which induce the body to become dependent upon something unnatural on a permanent basis. In the above sections, we gave a few examples of these drug dependent situations. In obesity cases, when a person뭩 metabolism becomes dependent upon a drug, this leaves the body permanently in need of this drug. As the body, in turn, becomes more resistant to this drug the person begins to need additional quantities. For example, if the diuretic agents are used too much, such a vital biological function as urination becomes dependent upon a drug. The long-term consequences of the unnecessary dependence can be quite severe.

6) Long-Term in Nature ?The methods should result in long-term weight loss and control. Once some weight is lost, it should stay lost at least for a long time and hopefully permanently. Short-term fluctuation of weight is not healthy. Sensible weight control methods should enhance the level of metabolism to a higher state, then, the weight control effects will stay for the long term. Otherwise, weight control effects are short-lived.

7) Convenience ?The method should be relatively easy to acquire and use.

We believe that there are sensible weight control methods that meet all the above seven criteria.

CHAPTER 4: A Sensible Combination of Four Weight Control Methods

Considering all the side effects, the other shortcomings of various weight control methods, and the fact that the re-normalizing the metabolic balance is at the core of the problem, we believe that obesity should be attacked with the combination of all of the following 4 methods:

1) Stress Management
2) Healthy Eating Habits
3) Regular Exercise and
4) Metabolism Boosting Dietary Supplement

Let뭩 examine each one more closely.

Stress Management

People tend to compensate for their stressful lives by finding different ways to relieve their stress. Some listen to music and some watch a movie. Some relieve their stress by having long conversations with their friends, and others believe in exercise. However, it is quite common that one way an overweight individual will respond to stress is by overeating.

Therefore, stress management is the first sensible thing one should do in order to fight obesity. In this regard, many proven relaxation techniques have been developed. Please review the ten relaxation techniques listed below and try to select two or three that will work for you. Stress is a major cause of numerous problems, we should all take steps to improve how we deal with stress as this will definitely improve our lives.

Stress Reducing Techniques:

1) Imagination ?Imagine a beautiful, comfortable and relaxing scenery or, situation.

2) Meditation ?Close yourself from all external interruptions and concentrate only on one peaceful subject.

3) Biofeedback ?Learn to take conscious control of the body뭩 inner physiological variables such as heart beat, blood pressure, skin temperature. Listen to your heart-beating and breathing and feel the calm it brings over your body.

4) Progressive Muscle Relaxation ?Lying down in a comfortable position, start flexing and then relaxing your various body-parts in a sequential manner. Start with one leg and move around the whole body.

5) Breathing Exercises – Concentrate on controlling the pace of your breathing. In a seated or laid position, start to relax by varying your breathing patterns from slow and deep to normal and shallow.

6) Aromatherapy – Relaxing your tension by using fragrances like roses and apple fragrance. Fragrances can be used to increase the pleasure and relaxation of a bath or for massage therapy.

7) Massage Therapy ?Practice makes perfect when it comes to becoming an effective masseuse or if you want to learn the basics take a couples massage class. This is a great way to relieve tension.

8) HydroTherapy ?Try floating in relaxing warm water.

9) Music Therapy – Use music to relax you and help you drift away.

10) Self-Hypnosis ?The repetition of self-motivating phrases or beliefs.

All the above relaxation techniques are quite well known and relatively safe. Fortunately, there are many qualified professionals who can help you learn and master your favorite relaxation techniques. They are also not that expensive. These relaxation techniques not only help you to control weight they provide many other health benefits. So make relaxation your first weight loss technique and we believe you will be pleasantly surprised.

Healthy Eating Habits

As we have said fasting or having an extremely low calorie diet that lacks nutritional balance is not a sensible means to control weight. Eating sensibly and properly is what brings the desired long-term results. Fortunately, eating sensibly is a well-developed subject that has a high level of public awareness and knowledge. Most people understand that they must regulate both the quality and the quantity of food consumed. We also know that a balanced diet, one that covers all four-food groups, is preferred. As there is many sources from which people can get the valuable information about this issue, we have not elaborated on this topic. However, this must be a key component of every sensible weight loss program.

Regular Exercise

Exercise has a direct effect on reducing a person뭩 body fat and blood sugar surplus. Regular exercises also stimulates the metabolism and revitalizes the production of insulin. An increased metabolism and insulin circulation in the blood stream will boost blood sugar consumption or processing, and improve insulin sensitivity. Exercise, any kind of increased movement, is extremely beneficial. Like healthy eating, there is so much great literature on the benefits of exercise, that we will just add a few comments.

For obesity patients, we recommend exercises that involve the whole body and are low in intensity level so that the person can maintain the exercise for over 30 minutes. Light exercises such as, walking, jogging, cycling, cross-country skiing, and easy mountain climbing are ideal. The goal is try and use all the major muscle groups so that the person slowly develops more muscle mass. Severely obese people should consult with their doctor to find a suitable exercise program. Consistency and developing a daily routine that makes exercise a top priority must be your goal.

One last thing about regular exercise as a weight control method. We recommend that you stay away from swimming if you can. Swimming is not as helpful in reducing weight as many believe. When you body is consistently in relatively cold water, it develops a defensive system against this cold. This defensive system is a layer of fat. Also since the body is floating in water when you swim, the effect of gravity is not as strong as during other exercises. This results the person burning fewer calories. This reduces the weight loss efficiency of swimming. Also, swimming has been shown to increase the appetite. So unless, your swimming is very vigorous, we would recommend another fitness exercise.

Metabolism Boosting Dietary Supplement

The above three methods (stress management, healthy eating habits, and proper exercise) are very fundamentally sound weight control methods. Unless poorly done, they do not have side effects. They also address the core of the obesity problem ?the metabolism imbalance. Stress management techniques assist an individual to avoid dangerous overeating that can result from their reaction to high stress levels. A balanced diet is essential to ensure intake of food calories is balanced with energy consumption. Physical fitness and exercise increases the muscle mass of the body thus increasing the metabolism. Thus all three methods are effective, safe and sound components to any weight loss program.

However, they do not seem to be enough. If they were enough, you would not be reading this booklet. These weight control methods have been known for a long time. If they were sufficiently effective, then the obesity problem would not be escalating through out the world. We suspect that the above methods are truly effective only during the initial stage of obesity. However they are not so effective during severe stages of obesity. When the basic energy metabolism itself is in a wrong cycle or during a later stage of obesity, the above three methods are not enough. In other words, the above three weight control methods are good enough for healthy people to maintain a healthy metabolism and they will also help control cases where people are mildly overweight. But, once the vicious cycle of obesity sets in, the above three methods alone are not sufficient to stop this cycle. In such cases, the above three methods should be assisted by metabolism booster which is both safe from side effects and effective. Eleotin-Mb is such a product. In Chapter 5, we will provide a brief history of this product and review how Eleotin-Mb works to provide a long-term weight loss solution.

Statistical Summary of Effects of Eleotin

Summary

An analysis done in 1999 shows that
1) A typical user was a 53.6 years old patient who had been diabetic for 9.8 years and whose initial BGL was 297.3 mg/dl. He used Eleotin for 3.9 months and his BGL dropped to 167.1 mg/dl.
2) A null hypothesis (H1: There is no difference in BGL reduction between the user group and control group) is rejected in favor of an alternative hypothesis (H2: the reduction of BGL in the user group is higher than that of control group) at a confidence level higher than 99%. We also found out that as long as the control group is given a therapy which reduces BGL by less than 70 mg/dl, the null hypotheses will be rejected at a confidence level of  95%.
3) A null hypothesis (H1: the length of Eleotin usage does not affect the size of the reduction of BGL) is rejected in favor of an alternative hypothesis (H2: the length of Eleotin usage increases the size of the reduction of BGL) at a confidence level higher than 99%.
4) Eleotin is not only effective in reducing the levels of BGL, but also very effective in reducing the fluctuation of BGL. It also prevents hypoglycemia.
5) Most of the statistical explanation in the user group is attributable to those who used Eleotin for more than 3 months.
6) The younger person experienced more drops in BGL in response to Eleotin. But, the ages of patients were not a dominant determinant of the Eleotin’s effects.  The years of diabetes is not really an important factor, either.  The sexes of the patients were not an important factor, either.  In other words, we can say that if one uses Eleotin for more than 3-4 months, people are quite likely to experience significant reductions in BGL regardless of their ages, sexes, and the years of diabetes, even though younger, male and newer patients did slightly better.

Statistical Analysis of Eleotin’s Effects

1999/11/25

1. Introduction

in what follows, we investigate the following questions:

Question 1: Is Eleotin effective in reducing the blood glucose levels (BGL) of diabetic patients?

Question 2: Is Eleotin effective when used less than three months?

Question 3: Is the age of a patient an important factor in the determination of effectiveness?

Question 4: Is the years of diabetes an important factor in the determination of effectiveness?

Question 5: Is there a tendency that the higher the initial BGL is, the more evident the effects are?
In order to investigate the above questions we use the data of

1) User Group: 80 patients who used Eleotin during the period of 1998 and 1999 and whose BGL’s before and after the usage were monitored by physicians and/or labs and whose years of diabetes and ages were reported, and

2) Control Group: 20 patients whose BGL before the usage and after were monitored by physicians and/or labs and whose years of diabetes and ages were reported during the same period

2. The results

In Table 1-A, we report the BGL changes of the user group

Table 1-A) BGL changes of User Group

  1. mon= Months of Eleotin Usage
  2. yd= Years of Diabetes
  3. age=Age of users
  4. BGLb= BGL before Eleotin in mg/dl
  5. BGLa=BGL after Eleotin in mg/dl
  6. Changeb=BGLa-BGLb: Reduction of BGL in mg/dlA typical user was a 53.6 years old patient who had been diabetic for 9.8 years and whose initial BGL was 297.3 mg/dl. He used Eleotin for 3.9 months and his BGL dropped to 167.1 mg/dl. They all maintained their pre-Eleotin therapies and they added Eleotin to their pre-Eleotin therapies. In Table 1-B, we report the changes of the BGL in the control group during the same period

Table 1-B) BGL changes of Control Group during the same period

  1. mon= Months of Eleotin Usage
  2. yd= Years of Diabetes
  3. age=Age of users
  4. BGLb= BGL before Eleotin in mg/dl
  5. BGLa=BGL after Eleotin in mg/dl
  6. Changeb=BGLa-BGLb: Reduction of BGL in mg/dlA typical person in the control group was a 53 year old person who had been diabetic for 8 years and starting BGL was 218 mg/dl, while at the end of the period, BGL was 211 mg/dl. They all maintained their current therapies.

3. Interpretations and Statistical Hypotheses Testing
1. Variances and Co-variances among Variables and Related Hypotheses Testing

We report in Tables 2-A and 2-B) the variances and co-variances of the variables in the user group and control group statistics.
Table 2-A) : variances and co-variances of the variables of user group statistics

Table 2-B) Variances and Covariances of Variables of Control Group statistics

mon= Months of Eleotin Usage

yd= Years of Diabetes

age=Age of users

BGLb= BGL before Eleotin in mg/dl

BGLa=BGL after Eleotin in mg/dl

Various tests show that a null hypothesis (H1: There is no difference in BGL reduction between the user group and control group) is rejected in favor of an alternative hypothesis (H2: the reduction of BGL in the user group is higher than that of control group) at a confidence level higher than 99%. For example, a linear regression model [Changeb = a + b(E): E=1 when Eleotin is used, E=0 when Eleotin is not used] produces 4.75 as a t value for the estimate for b, suggesting that the chance of usage of Eleotin not creating any better BGL reduction than the non usage is less than 1%. Eleotin user group seems to have experienced more BGL reduction than the control group. There seems to be no question about that. As was reported above, the user group showed an average drop of 130 mg/dl, while the control group showed an average drop of only 7 mg/dl. A high confidence level in any statistical investigation is natural.

Also, there is a high correlation between mon and BGLb: In the sample, people with serious people reported more months of usage: There is a highly negative correlation between mon and BGLa: A couple of test from the above statistics shows that a null hypothesis (H1: the length of Eleotin usage does not affect the size of the reduction of BGL) is rejected in favor of an alternative hypothesis (H2: the length of Eleotin usage increases the size of the reduction of BGL) at a confidence level higher than 99%. Later, in this study, we will report a few of these tests under a few different test designs.

Also noteworthy is that in the user group the variance of BGLa is only 26% of the variance of BGLb. It means that while before Eleotin usage BGL’s are very wildly dispersed across the individuals, after Eleotin BGL’s are relatively concentrated toward the normal level. This interpersonal BGL stabilization, together with HbA1c reduction prevalent across all the users strongly suggests that Eleotin is not only effective in reducing the levels of BGL, but also very effective in reducing the fluctuation of BGL. In this regard we report the changes in GTT’s of Users 64-70 in Table 2-C in which the fluctuations of GTT’s from 0 minutes to 120 minutes become smaller for all the users as a result of Eleotin therapy. 50% drop in variance is normal.

Table 2-C) GTT’s (30, 60, 120 minutes) of Users 64-70

This corroborates our previous finding that Eleotin improves the insulin sensitivity (see Therapeutics of Eleotin: www.Eastwoodcos.com Science Section ) This also suggests that Eleotin helps patients to fight hypoglycemia, as well as hyperglycemia. Furthermore, we report that for Users 53 to 59, who are Type I patients, the daily fluctuations of BGL, calculated as variance of Before Breakfast, Morning, Afternoon, Before Bed BGL, reduced by more than 15% to 40%.

Further, we looked at Table 3)

Table 3) Variances and Covariances of Variables in User Group

mon= Months of Eleotin Usage

yd= Years of Diabetes

age=Age of users

BGLb= BGL before Eleotin in mg/dl

BGLa=BGL after Eleotin in mg/dl

Changeb = BGLa-BGLb: Reduction of BGL in mg/dl

3.2. Ordinary Least Square (OLS) Regression Analysis and Related Hypothesis Testing

We performed an OLS regression on the BGL reduction related statistics from the user group with a simple linear model: Change in BGL = a + b(mon) + c(yd) + d(age) + e(BGLb).

Table 4) Result of Ordinary Least Square Regression of the user group

R square value was 0.87

We observe that there is a serious reduction in the level of BGL variance as a result of Eleotin. In order to compare the user group with the control group, a comparison was done by way of performing OLS on the control group: The result is shown in Table 5)

Table 5) OLS for control group

The same liner model was used : Change in BGL = a + c(yd) + d(age) + e(BGLb)

R square value was 0.6

It was very difficult to attach any interpretation to the statistical results of the control group with a low value of R square. The only variable which gives statistically somewhat significant explanation is the years of diabetes. Statistically, we are better off by not attempting any interpretations for these control groups.

A null hypothesis (H1:Changes of BGL in the two groups are identical) is rejected in favor of an alternative hypothesis (H2: Change of BGL in the user group is larger than the changes of BGL in the control ) at a confidence level higher than 99%. A linear regression model [Changeb = a + b(E): E=1 when Eleotin is used, E=0 when Eleotin is not used] produces 4.75 as a t value for the estimate for b, suggesting that the chance of usage of Eleotin not creating any better BGL reduction than the non usage is less than 1%.

If we perform an OLS for those people who used Eleotin less than 3 months, the results are

Table 6) OLS for those who used Eleotin less than three months

Change in BGL = a + c(yd) + d(age) + e(BGLb)

R square is 0.46

We compared the above Table with Table 7 in below.

Table 7) OLS for those who used Eleotin for more than 3 months

Change in BGL = a + c(yd) + d(age) + e(BGLb)

R square is 0.93

Comparison of Tables 4, 6, 7) shows that most of the statistical explanation in the user group is attributable to those who used Eleotin for more than 3 months.

For those people who used Eleotin for less than three months, we were reluctant to draw statistically strong conclusions that Eleotin is working even though the average BGL drop is from 251 to 187. We simply needed a larger sample to allow us such conclusions. For those who used more than 3 months, it is very obvious that the reduction of BGL happens almost surely. (R square is 93!) We could make a very strong statement. We can temporarily conclude that for those who used Eleotin for less than 3 months, we can still expect a significant drop in BGL. The drop will be in the range of 30-40% on the average, but, a chance of a particular person’s experiencing such results is less than 50%, while if a person uses Eleotin for more than 3 months, then, it is almost sure that the person experiences significant drop in BGL. But, it should also be pointed out that in this current study most of the explanation comes from those people who used for more than 3 months. This suggests that in the future study, the researcher should design the samples in such a way that the sample size of the people who uses for less than 3 months should be a lot larger than the current study. We believe that in order to attain the same level of statistical sharpness the sample size of the people with less than 3 months usage should be three to four times larger than those people who used more than 3 months.

We further report Tables 8 and 9)

Table 8) OLS results for those whose initial BGL is higher than 200

R square is 0.7

Table 9) OLS results for those whose initial BGL is lower than 200

R square is 0.44

Here again, the contribution to the explanatory power by low initial BGL group is ambiguous. R square is only 0.44.

In sum, the contribution to the explanation power from those people who used Eleotin for more than 3 months and with starting BGL less than 200 are statistically ambiguous even though the averages are dropping significantly. Most of the statistical explanation came from those people who took Eleotin for more than 3 months with starting BGL higher than 200. This suggests that in the future study, the sample sizes should be greatly expanded in those groups whose contribution to the explanation is statistically ambiguous. In the mean time, there is no doubt that the higher beginning BGL is, the more drop results from Eleotin usage.

The ages of the patient is of course negatively related to the BGL drop. The younger person experience more drop in BGL in response to Eleotin. But, it is not dominant. The Year of diabetes is not really important either. The effects of Eleotin can be said to be statistically independent of ages of the patients and the years of suffering. This is somewhat different from the intuitions we had before this test. We had thought that the younger people and the more recent patients would show better responses to Eleotin. But, it did not turn out to be the case. The starting BGL and whether a person uses more than three month jointly are dominantly important factors from the statistical viewpoint at least for the user group in this study.

For practical purposes, one may build a quite reliable forecaster form Table 7) in such way that if a patient uses Eleotin more than three months,

Reduction in BGL is predicted quite reliably to be -1.08 (mon) + 0.05(yd) – 0.83(age) + 0.88 (BGLb)-72.

For example, if a 55 year old patient whose initial BGL is 300 mg/dl and has been diabetic for 10 years, we can expect quite safely that if he uses Eleotin 4 months, BGL will drop by 142.5 mg/dl.

3. Other Observations (1): Type I patients

7 users were Type I patients (from User I.D 53 to 59). The infants (User I.D 58 to 59) took one quarter of the dosage which is 2 grams of Eleotin A, 2 grams of Eleotin B and two grams of Eleotin C. The changes of their insulin usage and some of other interesting figures are recorded in Table 10-A)

Table 10-A) Additional information on Users 53 to 59 who are Type I diabetic
User I.D. Starting Insulin Current Starting HbA1c Current StartingC-peptide Current Changeb

Because there were only 7 samples were available, we stayed away from drawing any statistical conclusions. But, the observations were encouraging. All of them showed significant drops in their BGL’s. The testing for Type I patients may require longer periods.

3.5. Other observations (2): Dosage

Users 71 to 80 used full dosages 8 grams of Eleotins A B C each day, while all others, except users 58 and 59, who were infants and used one quarter dosage, used half dosages, that is to say, 4 grams of A B and C each day. There was another study the result of which is still to come, in which quarter dosage was tried on adults for the two months. The results were not impressive at all. Out of 17, none showed any change in their BGL. After two months, all the patients in that study doubled the dosage. Then, almost everybody showed clear reduction in BGL. We are still waiting for the data. At this moment, we still do not know whether the reduction in BGL is attributable the ‘3 month’ symptom mentioned above, or, the effect is dosage specific. Further study in this area is warranted.

3.6. Other Observations (3): Other therapies

In Table 11, we show the other therapies patients had when they started Eleotin therapy. They were all instructed to maintain these therapies all throughout the trial. But, more than half of them either reduced the dosages of their other therapies or completely suspended all other therapies. Their non-compliance was due to the fact that some of them began to experience hypoglycemia as Eleotin began to take effects.

As the sample size grows, it would be possible in the future studies to establish when and how much current therapy can be replaced

Table 11. Other Therapies When Patients Started Eleotin.

O: Oral Hypoglycemic Agents

I: Insulin

Empty cells represent either that patients were not taking any other therapies or that the patients stopped all other therapies. Other therapies at the end of the trial will be reported in the future study. In the meantime, please refer to section 4.2 which mentions the comparative therapeutic values of Eleotin.

3.7. Other Observation (4): Prevention of Hypoglycemia

As usual, we started by assuming that the BGL is governed by a normal distribution with an identical independent distribution. Fortunately, multicollinearity and heteroscedasticity were not serious so that we could afford to use simple OLS methods without sacrificing the unbiasedness and efficiency in statistical estimation. With this small sample size, it was a very valuable luck.

However, we should add one caveat about this linearity of the model. Even though the above linear model shows quite impressive statistical fitness, we still believe that a non linear model should be used in the future studies on a priori ground. Also, we maintain that such non-linearity would clearly show that the therapeutic value of Eleotin consists not only of the reduction of level of BGL in case of hyperglycemia, but also, preventing hypoglycemia.

The reason for the necessity of a non-linear model can be best explained by way of an example. In the conclusions of section 3.2, we mentioned a predictor. According to the predictor, when the initial BGL is below {72+0.83 (age) +1.08 (mon) –0.05(yd)}/0.88, the usage of Eleotin increases BGL instead of decreasing BGL. If we insist upon using the above linear predictor without any modifications, the average person in the control group who is 53.6 year old person with 9.8 years of diabetes should have at least 136.6 mg/dl BGL, otherwise, he would not benefit from Eleotin at all. This is not the case from the observations of more than 7,000 users, animal tests, and, pharmacological data. Therefore we infer that a kink for the predictor should happen before around 130 mg/dl range. In other words, for the ranges of initial BGL lower than 130 mg/dl, we have a good reason why the above predictor should not be used unless modified. A predictor with higher intercept and lower coefficient for BGLb should be used. What we know is that for the low initial BGL range there should be more samples to attain the same sharpness in the predictor, which is quite consistent with our intuition.

The existence of such kinks and reduction of the absolute value of the slope as BGLb becomes smaller suggest that Eleotin not only reduces BGL levels, but, prevents hypoglycemia. This results are consistent with the findings of section 3.1 where it is reported the contribution of Eleotin to the reduction of the fluctuations of BGL, as well as the reduction in the level of BGL.

3.8. Sexes and Alcohol Consumption

The sexes of patients affected the changes of BGL in responses to Eleotin, but, not significant enough to be detected at the confidence level of 95%. We ran a linear regression Changeb = a + b (S) where S is one if male, 0 otherwise. The t value for the regression in the user group is 1.67.

We have reason to believe that alcohol consumption adversely affects the response to Eleotin. The responses were not recorded in the above because all the patients who consumed alcohol during the therapy did not show tangible improvement in their control of BGL, and dropped out of the test. There were 4 such patients.
4. Comments on Methodology

4.1.Sampling and Degrees of Freedom

Many individual variations such as weight, other diseases, etc. are suppressed in order to optimize the degree of freedom in the above statistical study. In other words, we had to stop somewhere in our adding new explanatory variables unless there is accompanying increase of the sample size. We applied the author’s discretion in the selection of the explanatory variables. But, we have the data on other variables so that we can add more explanatory variables in the future studies with larger samples.

4.2. Comments on Control Group: Sensitivity Study of the Confidence Levels and Dosages.

Even though we use the term ‘Control Group’, we warn you that we did not follow the traditional protocol which is called a ‘double blind’ test in which fixed placebos are given.

Instead, we designated and observed a group of patients during the test period. We did not give them placebos.

Then we ran a series of linear regressions

[Changeb = a + b(E): E=1 when Eleotin is used, E=0 when Eleotin is not used, and, the control group’s changes in BGL is raised by 100 mg/dl]

[Changeb = a + b(E): E=1 when Eleotin is used, E=0 when Eleotin is not used, and the control group’s changes in BGL is raised by 70mg/dl]

[Changeb = a + b(E): E=1 when Eleotin is used, E=0 when Eleotin is not used and control group’s changes in BGL is raised by 50mg/dl]

The changes in the t values for the estimates of b in the above linear model are as follows

When raised by 100 mg/dl, the t value is 1.09. When raised by 70 mg/dl, the t value is 2.06, and when raised by 50 mg/dl, the t value is 2.83. In other words, the usage of Eleotin will show statistically significant difference from the performance of any control groups as long as the control group were given a placebo, or, an alternative therapy which gives 70 mg/dl reduction in the BGL. In other words, the Eleotin can perform significantly better than whatever the patients use to reduce their BGL by 70 mg/dl. This result will help us to determine for whom switching from the current therapy to Eleotin is beneficial. If the current therapy belongs to any of the following category, a gradual switching to the Eleotin therapy should be seriously considered.

  1. Current therapy reduces BGL by less than 70 mg/dl.
  2. Current therapy has known side effects.
  3. Current therapy has known resistance.
  4. Current therapy has to continue indefinitely.
  5. Current therapy causes hypoglycemia
  6. Current therapy increases the fluctuations of BGL over the long run.


5. Summary

  1. A typical user was a 53.6 years old patient who had been diabetic for 9.8 years and whose initial BGL was 297.3 mg/dl. He used Eleotin for 3.9 months and his BGL dropped to 167.1 mg/dl.
  2. A null hypothesis (H1: There is no difference in BGL reduction between the user group and control group) is rejected in favor of an alternative hypothesis (H2: the reduction of BGL in the user group is higher than that of control group) at a confidence level higher than 99%. We also found out that as long as the control group is given a therapy which reduces BGL by less than 70 mg/dl, the null hypotheses will be rejected at a confidence level of 95%.
  3. A null hypothesis (H1: the length of Eleotin usage does not affect the size of the reduction of BGL) is rejected in favor of an alternative hypothesis (H2: the length of Eleotin usage increases the size of the reduction of BGL) at a confidence level higher than 99%.
  4. Eleotin is not only effective in reducing the levels of BGL, but also very effective in reducing the fluctuation of BGL. It also prevents hypoglycemia.
  5. Most of the statistical explanation in the user group is attributable to those who used Eleotin for more than 3 months.
  6. The younger person experienced more drops in BGL in response to Eleotin. But, the ages of patients were not a dominant determinant of the Eleotin’s effects. The years of diabetes is not really an important factor, either. The sexes of the patients were not an important factor, either. In other words, we can say that if one uses Eleotin for more than 3-4 months, people are quite likely to experience significant reductions in BGL regardless of their ages, sexes, and the years of diabetes, even though younger, male and newer patients did slightly better.

References:

Therapeutics of Eleotin:

Koutsoyiannis, Theory of Econometrics (Second Edition Macmillan Press Ltd. Toronto, 1977)

Richard Larsen and Morris Marx An Introduction of Mathematical Statistics and Its Implication (Prentice Hall, Inc., Englewood Cliffs, N.J. 1981)

Studies and Researches on Ingredients of Eleotin

성분1)

한국명: 녹차             중문명 : 茶葉

영문명: Green Tea        라틴학명 : Thea Sinensis Leaf

[根據藥典 ]

1) 湯液本草

2) 雷公 制藥性解

3) 本草求眞

4) 本草經集注

5) 千金·食治

6) 唐本草

7) 食療本草

8) 本草拾遺

9) 本草別說

10) 日用本草

11) 本草綱目

12) 本草通玄

13) 隨息居飮食譜

14) 本草圖經

15) 爾雅

16) 茶經

17) 聖濟總錄

18) 簡便單方

19) 萬氏家抄方

20) 醫方集聽

21) G. Nonaka et al. : Chem. Pharm. Bull., 31, 3906 (1983)

22) Itiro Yosika, et al. : Chem Pharm. Bull., 18(8) 1621 (1970)

23) Idem. Ibid 18(8) 1610 (1970)

24) Hisayuki Tanizawa, et. al., : Chem Pharm. Byll., 32(5) 2011 (1984)

25) Fumio Hashimoto, et al., : Chem Pharm. Bull ., 36(5), 1976 (1988)

26) Idem. Ibid 35(2), 611 (1987)

[處方名例 ]

1) 茶柏散

2) 茶調散

3) 薑茶散

4) 海金砂散

[成分關聯文獻 ]

1) 徐國鈞 : 藥材學 416, 1963

2) 樓之岑 : 生藥學 354, 1965

3) 中草藥有效成分的硏究 <第 1分冊 > 376, 1972

4) C.A. 67 : 11613m, 1967

5) 醫學中央雜誌 <日 > 276 : 452, 1971

6) C.A. 77 : 58728z, 1972

7) 醫學中央雜誌 <日 > 285 : 470, 1972

8) 醫學中央雜誌 <日 > 297 : 264, 1973

9) 醫學中央雜誌 <日 > 276 : 452, 1971

[藥理關聯文獻 ]

1) 張昌紹 : 藥理學 89, 1965

2) 中華醫學 44 <5> : 472, 1968

3) 南京藥學院學報 <2> : 61, 1957

4) 上海中醫藥雜誌 <3> : 38, 1958

5) 靑島醫學院學報 <2> : 7, 1959

6) 重慶市衛生局 : 醫學科學論文選集 : 1 : 198, 1959

7) 云南醫學雜誌 <2> : 20, 1959

8) 昆明醫學院 : 學術簡  31, 1960

9) 中華醫學 46 <4> : 319, 1960

10) 中華醫學 38 <9> : 810, 1952

11) 微生物學報 8 <1> : 48, 1960

12) 昆明醫學院 : 學術簡  41, 1960

13) 中華醫學 <9> : 740, 1954

14) 福建中醫藥 8 <3> : 31, 1963

15) A. Manual of Pharmacology ( Sollmann, T.) 8Ed 268, 1957

16) U.S. Dispensatory 24 Ed. 1624, 1947

[臨床報道關聯文獻 ]

1) 人民健康 <7> : 609, 1959

2) 新醫學報 <1> : 7∼ 11, 1960

3) 南京軍區衛生部 : 醫學交流會議資料 編 <祖國醫學 > 22∼ 6, 1959

4) 上海中醫藥雜誌 <6> : 13, 1963

5) 中華內科 9 <2> : 127, 1961

6) 遼寧醫學雜誌 <5> : 29, 1960

7) 山東醫刊 <4> : 29∼ 30, 1963

8) 中醫雜誌 <8> : 525, 1959

9) 中華兒科 10 <1> : 21 ∼2, 1959

10) 中華內科 <7> : 681, 1961

11) 中醫雜誌 <11> : 784 ∼5, 1958

12) 中華皮膚科 <1> : 78, 1959

13) 浙江中醫雜誌 6 <1> : 10, 1963

14) 武漢醫學雜誌 3 <5> : 473, 1966

15) 廣東中醫 4 <7> : 294 ∼6, 1959

16) 江西醫藥 5 <4> : 766 ∼7, 1965

17) 中國醫學科學院江西分院 : 醫學科學論文 編 <3> : 234∼ 8, 1961

18) 重慶市衛生局 : 醫學科學論文選集 <3> : 61∼ 3, 1959

19) 中華兒科 11 <3> : 234, 1960

20) 西安醫學院 : 科學硏究技術革新輯要 <1> 208, 1959

21) 二軍大學術資料 編   < 第14 集> 31 ∼2, 1962

22) 內蒙古衛生廳 : 醫藥衛生技術革新技術革命展覽會資料選編 151, 1960

23) 寧波市科技簡報 <1> 10, 1971

24) 江西中醫藥 <6> : 37, 1960

25) 廣東中醫 5 <7> : 326, 1960

 

성분 2)

한국명: 냉이            중문명 : 薺菜

영문명: Capsella Leaf    라틴학명 : Capsella Bursa

[根據藥典 ]

1) 千金·食治

2) 本草綱目

3) 醫林纂要

4) 植物名實圖考

5) 廣州植物誌

6) 貴州民間方藥集

7) 陸川本草

8) 四川中藥誌

9)  東本草

10) 浙江民間常用草藥

11) 上海常用中草藥

12) 廣西中草藥

13) 日用本草

14) 得配本草

15) 本草撮要

16) 別錄

17) 藥性論

18) 食經

19) 現代實用中藥

20) 南寧市藥物誌

21) 聖惠方

22) 聖濟總錄

23) 福建民間草藥

[處方名例 ]

1)   大丸

[成分關聯文獻 ]

1) C.A. 55 : 12551d, 1961

2) 江蘇藥材誌 467, 1965

3) C.A. 55 : 14823c, 1961

4) 藥學硏究 <日 > 33 <1> : 48, 1961

5) C.A. 49 : 15938c, 1955

6) C.A. 68 : 6223a, 1968

7) C.A. 64 : 10086c, 1966

8) C.A. 68 : 53225n, 1968

9) C.A. 60 : 14565c, 1960

10) 中央衛生硏究院 : 食物成分表 46, 1957

11) C.A. 55 : 12551d, 1961

[藥理關聯文獻 ]

1) 中藥的藥理 應用 231, 1958

2) 醫學中央雜誌 <日 > 218 : 561, 1966

3) 醫學中央雜誌 <日 > 206 : 493, 1965

4) 上海中醫藥雜誌 <1> : 15, 1957

5) C.A. 22 : 20039, 1928

6) C.A. 35 : 81032, 1941

7) C.A. 70 : 76342d, 1969

8) C.A. 31 : 67278, 1937

9) C.A. 35 : 37665, 1941

10) Arch. Intern. Pharmacodyn. Ther. 178 <2> : 382, 1969

11) Arch. Intern. Pharmacodyn. Ther. 178 <2> : 392, 1969

12) Medicinal and Poisonous Plants of Southern and Eastern Africa (Watt, J.M.) 2Ed.        329, 1962

[臨床報道關聯文獻 ]

1) 江蘇省中草藥新醫療法展覽資料選編 2, 1970

2) 中華外科 4 <12> : 948 ∼9, 1956

3) 長春醫學院 : 1958年科學硏究技術革新選集 28, 1958

4) 廣西醫學院 : 中草藥新醫療法展覽資料選編 62, 1970

 

성분 3)

한국명: 도라지             중문명 : 桔梗

영문명: Platycodon Root   라틴학명: Platycol Radix

[根據藥典 ]

1) 吳普本草

2) 別錄

3) 丹溪心法

4) 本草綱目

5) 江蘇植藥誌

6) 本經

7) 藥性論

8) 湯液本草

9) 品 精要

10) 本草經疏

11) 日華子本草

12) 本草衍義

13) 珍珠囊

14) 中藥形性經驗鑑別法

15) 本草經集注

16) 藥對

17) 本經逢原

18) 金 要略

19) 簡要濟衆方

20) 千金方

21) 傷寒論

22) 蘇沈良方

23) 衛生易簡方

24) 本草通玄

25) 本草求眞

26) 藥征

27) 重慶堂隨筆

28) 唐本草

29) Toshiyuki Akiyama, et al. : Chem. Pharm. Bull. 20(9), 1952 (1972)

30) Teniohi Konish, et al. : Chem. Pharm. Bull. 26(2),  663 (1978)

31) Toshiyuki Akiyama, et al. : Chem. Pharm. Bull. 16(11),  2300 (1968)

32) H. Ishii et al. : Chem. Lett., 719(1978)

: H. Kato et al. : Jpn. Pharmacol. : 23, 709 (1973)

33) Toshiyuki Akiyama, et al. : Chem. Pharm. Bull. 20(9), 1957 (1972)

34) Saito, Norio, et al. : Shoyakugaku Zasshi 85,  105 (1972)

[處方名例 ]

1) 桔梗散

2) 桔梗湯

3) 排膿湯

4) 必用方甘桔湯

5) 桔梗 角��

6) 桔梗白散

[成分關聯文獻 ]

1) C.A. 34 : 1375, 1940

2) C.A. 33 : 64481, 1939

3) C.A. 75 : 59778m, 1971

4) 醫學中央雜誌 <日 > 271 : 716, 1971

5) 醫學中央雜誌 <日 > 259 : 97, 1970

6) C.A. 70 : 29114w, 1969

7) 醫學中央雜誌 <日 > 203 : 705, 1965

8) Acta Phytochim < 日> 13 : 185, 1942∼ 3

9) C.A. 72 : 43919k, 1970

10) C.A. 74 : 142281u, 1954

[藥理關聯文獻 ]

1) 中華醫學 38 <5> : 4, 1952

2) 醫學中央雜誌 <日 > 80 : 179, 1943

3) 中華醫學 40 <5> : 331, 1954

4) 張昌紹 : 藥理學 <第 3版 > 189, 1965

5) 醫學中央雜誌 <日 > 61 : 434, 1939

6) 日本藥理學雜誌 67 <6> : 223, 1971

7) C.A. 68 : 20785s, 1968

8) 中華醫學 38 <4> : 315, 1952

9) 新中醫藥 8 <4> : 17, 1957

 

성분 4)

한국명: 둥글레          중문명 : 黃精

영문명: Pluriflorum      라틴학명 : Polygonatum Japonicum

[根據藥典 ]

1) 廣雅

2) 博物誌

3) 拘朴子

4) 別錄

5) 本草圖經

6) 靈芝瑞草經

7) 救荒本草

8)  南本草

9) 本草蒙筌

10) 廣西通誌

11) 本草備要

12) 本草從新

13) 辰溪誌

14) 草木便方

15) 嶺南采藥錄

16) 山西中藥誌

17) 中藥誌

18) 湖南農村常用中草藥手冊

19) 四聲本草

20) 雷公 制藥性解

21) 玉楸藥解

22) 本草再新

23) 日華子本草

24) 現代實用中藥

25) 四川中藥誌

26) 本經逢原

27) 得配本草

28) 本草正義

29) 奇效良方

30)  東本草

31) 山東中草藥手冊

32) 聖惠方

33) 聖濟總錄

34) 福建中醫藥

35) 唐本草

36) 食療本草

37) 本草求原

38) T. Namba : coloured Illustration of WAKAN-YAKU pp.152-153(1980) Hoikusha Pub.      Co. Ltd. JAPAN

39) 한약 (생약 )규격집 : 황정 P.433(1988) 보건사회부

40) 中山醫學院 : 漢藥의 臨床聽用 p.318(1979) 醫齒藥出版社

41) 陸昌洙 : 原色韓國藥用植物圖鑑 p.62-65 (1988) 아카데미서적

[處方名例 ]

1) 黃精湯

2) 黃精酒

3) 枸杞丸

[成分關聯文獻 ]

1) 徐國鈞 : 藥材學 671, 1963

2) C.A. 53 : 3382f, 1959

3) 中國藥植誌 8 : 400 圖 , 1965

4) C.A. 48 : 7711a, 1954

5) C.A. 72 : 24544t, 1970

[藥理關聯文獻 ]

1) 中華醫學 44 <5> : 430, 1958

2) 中華內科 <4> : 227, 1962

3) 四川醫學院學報 <1> : 2, 1960

4) 中華醫學 48 <12> : 781, 1962

5) 遼寧省·衛生防疫資料 (流行性感冒專輯 ) 62, 1972

6) 中華醫學 44 <5> : 434, 1958

7) 中國醫學科學院論文摘要 70, 1956

[臨床報道關聯文獻 ]

1) 浙江醫學 <4> : 163∼ 4, 1960

2) 中華醫學 <5> : 432∼ 8, 1958

 

성분 5)

한국명: 오미자             중문명 : 五味子

영문명: Schizandra Fruit   라틴학명: Schizandra Fructus

[根據藥典 ]

1) 爾雅

2) 吳普本草

3) 別錄

4) 遼寧主要藥材

5) 本經

6) 唐本草

7) 長沙藥解

8) 湯液本草

9) 本草綱目

10) 日華子本草

11) 本草衍義

12) 本草經集注

13) 千金方

14) 本草蒙筌

15) 本草通玄

16) 本草經疏

17) 本草正

18) 鷄峰普濟方

19) 衛生家寶方

20) 普濟方

21) 醫學入門

22) 本事方

23) 經驗良方

24) 談野翁試驗方

25) 本草新編

26) 注解傷寒論

27) 用藥心法

28) 本草衍義補遺

29) 丹溪心法

30) 本草會編

31) 本草 言

32) 藥品化義

33) 本經疏

34) 本草求原

35) 本草正義

36) 雷公 炙論

37) Chen, Yan-Yong et al. : Hua Hsueh Hsueh Pao 34(1) 45 (1976)

38) N. K. Kochetkov et al. : Terahedron Letters 730 (1961)

39) N. K. Kochetkov et al. : J. Gen. Chem. (U.S.S.R.) 31, 3454 (1961)

40) Spurnov, N. I. : Rast. Resur. 9 (4) 570 (1973)

41) Kim Kyung Im et al. : Hanguk Sikpum Kwahakhoe Chi 5(3) 178 (1973)

42) N. K. Kochetkov et al. : Terahedron Letters 361 (1962)

43) Y. Ikeya et al. : Chem Pharm. Bull. 27, 1583 (1979)

44) 池谷 , 田口 等 : [日本生藥學會 ] 第 26回年會 講演要旨集

45) Y. Ikeya et al. : Tetrahedron Letters(17) 1359 (1976)

46) Zakani, Masako et al. : Chem. Pharm. Bull. 25(12) 3388(1977)

47) KiKuchi, Matsuko et al.: Chem. Lett. (8) 725(1972)

48) Takahashi, Kotaro et al. : Chem. Parm. Bull. 23(3) 538(1975)

49) Yukinobu, Ikeya et al.: Chem. Pharm. Bull. 38, 1408(1990)

50) Maeda, S. et al. : Yakugaku Zasshi, 101, 1030(1981)

51) Maeda, S. et al. : Japan J. Pharmacol., 38, 347(1985)

: Hikino, H. et al. : Planta Medica, 213, (1984)

: Kiso, Y. et al. : Planta Medica, 313(1985)

[處方名例 ]

1) 五味子湯

2) 五味子丸

3) 五味子散

4) 五味子膏

5) 生脈散

6) 淸肺湯

7) 補肺湯

8) 大造丸

9) 小靑龍湯

10) 五味細辛湯

11) 蔘蘇溫肺湯

12) 究原心腎丸

13) 增益歸茸丸

14) 延齡固本丹

[成分關聯文獻 ]

1) Tetraherdon Lett. 1251, 1968

2) Tetraherdon Lett. 2483, 1968

3) Tetrahedron Lett. 4181, 1968

4) 中國藥植誌 5 : 222, 1957

5) Tetrahedron Lett. 361, 1962

6) Tetrahedron Lett. 730, 1961

7) C.A. 40 : 62742, 1946

8) 中藥誌

9) 化學學報 34(1) : 45, 1975

10) 中國科學 (1) : 98, 1976

[藥理關聯文獻 ]

1) 天津醫藥雜誌 7(4) : 338, 1965

2) 藥學學報 11(1) : 30, 1964

3) 中國生理科學會第 1 會員代表大會論文摘要 (藥 ) 59, 1956

4) 中國生理科學會第 1 會員代表大會論文摘要 (藥 ) 61, 1956

5) 巴甫洛夫高級神經活動雜誌譯叢 2(2) : 111, 1956

6) 巴甫洛夫高級神經活動雜誌譯叢 2(2) : 107, 1956

7) 中醫硏究院科技資料選編 123, 1972

8) 藥學學報 8(7) : 277, 1959

9) 中國醫學科學院 1956年論文報告會論文摘要 (II) 70, 1956

10) 中華醫學 41(10) : 959, 1955

11) C.A. 53, 10509b, 1959

12) 蘇聯醫學 9:31, 1952

13) 中山醫學院 : 新醫學 6 : 33, 1972

14) C.A. 41 : 56348, 1947

15) 中華醫學 41(5) : 479, 1955

16) 哈爾濱醫科大學校慶 10周年學術報告會論文 編 102, 1959

17) C.A. 55 : 4781f, 1961

18) C.A. 52 : 20682g, 1958

19) 植物學報 3 : 121, 1954

20) 遼寧醫學雜誌 (1) : 38, (9) : 24, 1960

21) 中國醫學科學院 : 醫學參考資料 (7) 32, 1972

22) C.A. 68 : 1870z, 1968

23) C.A. 67 : 20251u, 1967

24) 藥學學報 10(9) : 531, 1963

[臨床報道關聯文獻 ]

1) 中草藥通訊 (4) : 35, 1972

2) 湖北科技 (醫藥部分 ) (5) : 29, 1972

3) 上海中醫藥雜誌 (3) : 34, 1956

4) 北京中醫 3(4) : 25, 1954

5) 哈爾濱醫大 : 中西醫結合硏究論文集 (3) : 57, 1961

6) 大連醫學院 : 1955年級畢業論文選集 125, 1960

 

성분 6)

한국명: 두릅                  중문명 :  木白皮

영문명: Japanese Angelica     라틴학명 : Aralia Elata

[根據藥典 ]

1) 浙江民間草藥

2) 本草拾遺

3) 本草綱目

4)  東本草

5) 本草推陳

[成分關聯文獻 ]

中草藥有效成分的硏究 <第 1分冊 > 391, 1972

 

성분 7)

한국명: 상엽             중문명 : 桑葉

영문명: Mulberry Leaf    라틴학명 : Morus Alba

[根據藥典 ]

1) 本經

2) 百草經

3) 詩經

4) 日華子本草

5) 農書

6) 救荒本草

7) 醫林纂要

8) 本草綱目

9) 本草經解

10) 本草再新

11) 唐本草

12) 本草拾遺

13) 本草圖經

14) 丹溪心法

15) 本草蒙筌

16) 本草從新

17) 本草求原

18) 本草求眞

19) 山東中藥

20) 溫病條辨

21) 瀕湖集簡方

22) 養素園傳信方

23) 醫級

24) 聖濟總錄

25) 聖惠方

26) 勝金方

27) 仁齋直指方

28) 通玄論

29) 醫學正傳

30) 上海常用中草藥

31) 山東中草藥手冊

32) 草藥手冊 (江西 )

33) 本草經疏

34) 重慶堂隨筆

35) 本草撮要

[處方名例 ]

1) 獨聖散

2) 桑菊飮

3) 桑麻丸

[成分關聯文獻 ]

1) 醫學中央雜誌 <日 > 259 : 51, 1970

2) C.A. 51 <22> : 18140d, 1957

3) 醫學中央雜誌 <日 > 259 : 52, 1970

4) 化學總攬 <日 > 36 : 60, 1962

5) 化學總攬 <日 > 38 : 1391, 1964

6) 醫學中央雜誌 <日 > 222 : 144, 1967

7) C.A. 64 <5> : 7045c, 1966

8) C.A. 60 <12> : 14765e, 1964

9) 藥學雜誌 <日 > 87 <6> : 748, 1967

10) C.A. 49 <22> : 14052g, 1955

11) 化學總攬 <日 > 39 : 1351, 1965

12) C.A. 67 <1> : 776r, 1967

13) 化學總攬 <日 > 38 : 206, 1964

14) 昆蟲學報 12 < 4> : 432, 1963

15) 醫學中央雜誌 <日 > 195 : 528, 1964 ; 化學總攬 < 日> 38 : 42, 1964

16) C.A. 52 <20> : 17407i, 1958

17) C.A. 45 : 2544d, 1951

18) C.A. 48 : 9486a, 1954

19) 中國生理學雜誌 (英文版 ) 15 <1> : 13, 1940

20) 化學總攬 <日 > 36 : 720, 1962

21) 中草藥有效成分的硏究 <第 1分冊 > 414, 1972

22) C.A. 48 : 232g, 1954

[藥理關聯文獻 ]

1) C.A. 60 : 4650g, 1963

2) 中草藥通訊 <6>  : 32, 1972

3) 徐州醫學院 : 新醫學資料 <1> : 27, 1971

[臨床報道關聯文獻 ]

1) 中草藥通訊 <6>  : 32, 1972

2) 中國醫學科學院寄生蟲病硏究所 : 寄生蟲病防治硏究簡報 <7> : 17∼ 9, 1971

 

성분 8)

한국명: 달개비         중문명 : 鴨 草

영문명: Dayflower      라틴학명 : Commelina Communis

[根據藥典 ]

1) 本草拾遺

2) 本草圖經

3) 竹譜詳錄

4) 世醫得效方

5) 南本草

6) 活幼全書

7) 瀕湖集簡方

8) 本草綱目

9) 植物名實圖考長編

10) 植物學大辭典

11) 東北藥植誌

12) 貴陽民間藥草

13) 江西中藥

14) 四川中藥誌

15) 遼寧經濟植物誌

16) 常用中草藥手冊

17) 江西草藥

18) 浙江民間常用草藥

19) 上海常用中草藥

20) 廣西中草藥

21) 江蘇藥材誌

22) 福建中草藥

23) 日華子本草

24) 品 精要

25) 本草推陳

26) 泉州本草

27) 全展選編·傳染病

[成分關聯文獻 ]

1) C.A. 67 : 99951d, 1967

2) C.A. 54 : 25084a, 1960

3) C.A. 54 : 2501i, 1960

[藥理關聯文獻 ]

1) C.A. 38 : 36937, 50078, 1944

[臨床報道關聯文獻 ]

1) 總後衛生部 : 衛生簡報 ·增頁 <8> : 1∼ 7, 1971

2) 杭州市 ·衛生防疫資料 編 83 ∼4, 1972

3) 杭州醫藥 <2> : 27∼ 8, 1972

4) 中山醫學院 : 新醫學 <8> : 60, 1971

 

성분 9)

한국명: 감초            중문명 : 甘草

영문명: Licoric Root     라틴학명 : Glycyrrhizae Radix

[根據藥典 ]

1) 本經

2) 別錄

3) 記事珠

4) 群芳譜

5) 中國藥植誌

6) 中藥誌

7) 黑龍江中藥

8) 雷公 炙論

9) 本草綱目

10) 本草衍義

11) 珍珠囊

12) 湯液本草

13) 雷公 製藥性解

14) 本草通玄

15) 本草經解

16) 藥性論

17) 日華子本草

18) 中國藥植圖鑑

19) 本草經集注

20) 醫學入門

21) 局方

22) 金 要略

23) 聖濟總錄

24) 傷寒論

25) 草醫草藥簡便驗方 編

26) 單方驗方新醫療法選編

27) 中草藥新醫療法資料選編

28) 仁齋直指方

29) 幼幼新書

30) 怪證奇方

31) 養生必用方

32) 本草蒙筌

33) 健康報

34) 本草衍義補遺

35) 本草 言

36) 本草正

37) 藥品化義

38) 本草備要

39) 本經疏證

40) 千金方

41) 本草正義

42) 本草圖經

43) N.P. Kiryanov et al. : Zhur. Obshchei Khim. 34, 2814 (1964)

44) N.P. Kiryanov et al. : Khim. Prir. Soedin 1974, 10(1) 102

45) V.I. Litvinenko : C.A. 60, 6700 g

46) Miyuki Kaneda et al. : Chem. Pharm. Bull. 521, (6) 1338 (1973)

47) M.H.A. Elgamal et al. : Tetrahedron, 21, 2109 (1965)

48) M. De Oreglana Segovia : An Peal Acad. Farm. 38, 167 (1972)

49) V.I. Litvinenko et al. : Zhur. Obshchei Khim. 33, 296 (1963)

50) V.I. Litvinenko : Dokl. Akad. Nauk. S.S.S.R. 155, 600 (1964)

51) V.I. Litvinenko : Khim. Prir. Soedin 3, 56 (1967)

52) L. Canonica et al. : Gazz. Chim. Ital . 97, 1347 (1967)

53) L. Canonica et al. : Gazz. Chim. Ital. 97, 1359 (1967)

54) Van Hulle, C. et al. : Planta Media, 1971, 20(3) 278

55) Van Hulle, C. : Pharm. Tijdschr. Belg 1968, 45(7) 137

56) Saitoh Tamotsu. et al. : Chem. Pharm. Bull . 1976, 24(6) 1242

57) Balbaa, S.I. et al. : Bull. Fac. Pharm. Cairo Univ. 1975, (pub. 1976) 14(1) 213

58) Muravev, I.A. et al. : Rast. Resur 8(4) 490 1972

59) Saitoh Tamotsu. et al. : Chem. Pharm. Bull . 17(4) 729 1969

60) Kattaev. N. Sh. et al. : Khim. Prir. Soedin 1974, 10(1) 93

61) Shibata, Shoji et al. : Chem. Pharm. Bull . 16(10) 1932 1968

62) Bharadwaj. Devendra K. et al. : Phytochemistry 1976, 15(2) 352

63) Ingham. John, L. : Phytochemistry 1977, 16(9) 1457

64) V.I. Litvinenko. : Rast. Resur. 2, 531(1966)

65) L. Canonica et al. : Gazz. Chim. Ital. 96, 772 (1966)

66) Bogatkina, V.F. et al. : Khim. Prir. Soedin 1975, 11(1) 101-2

67) Doft. Invernie Della Beff. : S. P. A. Fr. Demande 2, 108, 908

68) Biorex. Lab. Ltd. : Ger 1.076, 684 Mar . 3, 1960(cl. 120)

69) Fisher. R.S. et al. : Excerpta Med. Int. Gongr. Ser 1976, 379

70) Hess, Hans J. et al. : U.S. 3, 934,027 (cl 424-309, Ablk), 20, Jan 1975

71) Ulmann, A. et al. : Endocrinology 97(1) 46(1975)

72) Turner, John Cameron et al. : Ger. Offen. 2001, 906(cl. conc Ablk)

73) Suetina, I.V. : Biol. Nauki(moscow) 1982, (8) 47-50

[處方名例 ]

1) 甘草散

2) 二甘湯

3) 甘穀散

4) 凉膈散

5) 四逆散

6) 桔梗湯

7) 淸心湯

8) 炙甘草湯

9) 甘草乾薑湯

10) 甘草瀉心湯

11) 藥甘草湯

12) 錢氏異功散

13) 四君子湯

14) 甘桔湯

[成分關聯文獻 ]

1) 徐國鈞 : 藥材學 341, 1963

2) 東北藥用植物原色圖誌 90, 1963

3) 藥學學報 2: 121, 1954

4) 藥學學報 11: 473, 1964

5) 樓之岑 : 生藥學 153, 1965

6) C.A. 61 : 14725f, 1964

7) C.A. 62 : 13186a, 1965

8) C.A. 60 : 6700g, 1964

8) C.A. 68 : 13206a, 1968

9) C.A. 68 : 49811h, 1968

10) C.A. 68 : 49810g, 1968

11) Tetrahedron 21 : 2109, 1965

12) C.A. 76 : 83552z, 1972

13) C.A. 70 : 106822e, 1969

14) 藥學雜誌 <日 > 54: 707, 1934

15) 醫學中央雜誌 <日 > 259 : 96, 1970

16) 醫學中央雜誌 <日 > 259 : 97, 1970

17) 醫學中央雜誌 <日 > 259 : 98, 1970

18) 中藥硏究文獻摘要 144, 1963

[藥理關聯文獻 ]

1) J. Exp. Med. 106 : 415, 1957

2) Lancet 259 : 381, 1950

3) C.A. 48 : 8399g, 1954

4) C.A. 48 : 14124a, 1954

5) 藥學學報 10 <11> : 688, 1963

6) J. Pharm. Pharmacol. 10 <11> : 687, 1958

7) J. Pharm. Pharmacol. 13Supp : 107, 1961

8) C.A. 49 : 12719c, 1955

9) 日本內科學會雜誌 43 <4> : 50, 1954

10) 北京醫學院學報 <1> : 60, 1959

11) 日本消化機病學會雜誌 54 <6> : 309, 1957

12) J. Clin. Endocrinol&Metabol. 16 : 338, 1956

13) Lancet 264 : 657, 1953

14) Brit. J. Pharmacol. 10 : 305, 1955

15) Lancet 264 : 663, 1953

16) C.A. 54 : 16662g, 1960

17) C.A. 50 : 14961g, 1956

18) 日本內科學會雜誌 45 : 1224, 1956

19) 日本內分泌學會雜誌 34 <4> : 304, 1958

20) 醫學中央雜誌 <日 > 134 : 464, 1957

21) J. Lab. Clin. Med. 47 <1> : 20, 1956

22) 日本內分泌學會雜誌 35 <3> : 285, 1959

23) C.A. 66 : 27559p, 1967

24) 醫學中央雜誌 <日 > 129 : 398, 1957

25) J. Pharm. Pharmacol. 12 : 300, 1960

26) 藥學學報 12 <1> : 50, 1965

27) C.A. 66 : 102232g, 1967

28) 日本內分泌學會雜誌 34 <8> : 745, 1958

29) 新中醫藥 9 : 658, 1958

30) 天津醫學雜誌 1 <5>

31) Biochem. J. 69 : 75, 1958

32) C.A. 67 : 107072k, 1967

33) J. Pharm. Pharmacol. 10 <10> : 613, 1958

34) 醫學中央雜誌 <日 > 234 : 128, 1968

35) C.A. 55 : 4750i, 1961

36) C.A. 66 : 1453v, 1967

37) Ind. J. Pharm. 27 <3> : 80, 1965

38) J. Pharm. Pharmacol. 12 <1> : 49, 1960

39) C.A. 69 : 25919u, 1968

40) 慶應醫學 44 <1> : 17, 1967

41) 醫學中央雜誌 <日 > 150 : 248, 1959

42) 內科の 領域 <日 > 5 <6> : 421, 1957

43) 醫學中央雜誌 <日 > 271 : 312, 1971

44) 醫學中央雜誌 <日 > 207 : 558, 1965

45) 藥學雜誌 <日 > 89 <7> : 887, 1969

46) 慶應醫學 47 <4> : 331, 1970

47) 日本藥理學雜誌 65 <4> : 153 §, 1969

48) J. Pharm. Pharmacol. 19 <8> : 533, 1967

49) 日本藥理學雜誌 65 <6> : 227 §, 1969

50) 日本內科學會雜誌 44 <3> : 73, 1955

51) 日本內科學會雜誌 45 <5> : 476, 1956

52) 醫學中央雜誌 <日 > 215 : 239, 1966

53) C.A. 51 : 3021g, 1957

54) C.A. 52 : 14848g, 1958

55) C.A. 45 : 5881i, 1951

56) C.A. 52 : 6630a, 1958

57) 醫學中央雜誌 <日 > 240 : 785, 1968

58) 醫學中央雜誌 <日 > 285 : 569, 1972

59) C.A. 71 : 111219p, 1969

60) 日本消化機病學會雜誌 54 <2> : 87, 1957

61) C.A. 69 : 1648d, 1968

62) 中華生理學會第一屆會員代表大會會議論文摘要 < 藥> 79, 1956

63) 醫學中央雜誌 <日 > 276 : 345, 1971

64) 藥學雜誌 <日 > 89 <7> : 899, 1969

65) C.A. 48 : 11646c, 1954

66) 醫學中央雜誌 <日 > 221 : 265, 1966

67) 醫學中央雜誌 <日 > 97 : 357, 1952 ; 134 : 464, 1957

68) 日本消化機病學會雜誌 54 <6> : 308, 1957

69) 上海中醫藥 <10> : 17, 1957

70) C.A. 50 : 14961i, 1956

71) C.A. 50 : 6683h, 1956

72) C.A. 59 : 8027c, 1963

73) C.A. 50 : 6748g, 1956

74) Medical and Poisonous Plants of Southern and Eastern Africa (Watt, J. M.) 609,         1962

75) 藥學雜誌 <日 > 89 <7> : 893, 1969

76) 醫學中央雜誌 <日 > 218 : 562, 1966

77) 醫學中央雜誌 <日 > 126 : 207, 1956

78) 醫學中央雜誌 <日 > 177 : 481, 1962

79) 藥學硏究 <日 > 28 <6> : 58, 1956

80) 醫學中央雜誌 <日 > 186 : 697, 1963

81) 日本藥理學雜誌 53 <5> : 166 §, 1957

82) 中華醫學 41 <10> 951, 1955

83) 醫學中央雜誌 <日 > 129 : 399, 1957

84) 醫學中央雜誌 <日 > 136 : 771, 1958

85) 醫學中央雜誌 <日 > 137 : 900, 1958

86) 藥學通報 10 <4> : 160, 1964

87) 中華醫學 42 <8> 781, 1956

88) 江西醫學院學報 <2> : 43, 1959

89) 醫學中央雜誌 <日 > 280 : 718, 1972

90) 醫學中央雜誌 <日 > 150 : 248, 1959

91) 湖北醫學院學報 <10> : 59, 1959

92) 藥學硏究 <日 > 22 <10> : 418, 1950

93) 醫學中央雜誌 <日 > 110 : 130, 1954

94) 醫學中央雜誌 <日 > 177 : 212, 1962

95) 醫學中央雜誌 <日 > 219 : 498, 1966

96) 中華醫學 42 <8> 755, 1956

97) C.A. 27 : 339, 1933

98) PVルギ 2 <6> : 332, 1954

99) 醫學中央雜誌 <日 > 137 : 900, 1958

100) 臨床內科小兒科 <일 > 15 <1> : 89, 1960

101) 醫學中央雜誌 <日 > 126 : 207, 1956

102) 醫學中央雜誌 <日 > 280 : 717, 1972

103) 藥學學報 13 <5> : 350, 1966

104) 江西醫學院學報 <3> : 1, 1959

105) 中國生理科學會學術會議論文摘要 編 < 藥理> 136, 1964

106) C.A. 13 : 1618, 1919

107) 醫學中央雜誌 <日 > 155 : 70, 1960

108) 日本藥理學雜誌 55 : 152§ , 1959

109) 醫學中央雜誌 <日 > 207 : 288, 1965

110) 日本藥理學雜誌 55 : 153§ , 1959

111) 日新醫學 47 <7> 454, 1960

112) 生化學 <日 > 30 <3> : 246, 1958

113) 醫學中央雜誌 <日 > 223 : 26, 1967

114) 醫學中央雜誌 <日 > 206 : 640, 1965

115) C.A. 71 : 11681q, 1969

116) 日本臨床 , 18 <5> : 930, 1960

117) 日本醫事新報 1843 : 20, 1967

118) 最新醫學 <日 > 16 <1> : 209, 1961

119) 江蘇新醫學院 : 中藥活血化瘀類藥物及某些合成藥對實驗性動脈粥樣硬化的療效觀察 , 1972

120) C.A. 70 : 2230u, 1969

121) C.A. 66 : 26946a, 1967

122) 日本藥理學雜誌 61 <6> : 130 §, 1965

123) C.A. 69 : 94889w, 1968

124) C.A. 69 : 94888v, 1968

125) 醫學中央雜誌 <日 > 276 : 281, 1971

126) C.A. 69 : 94890q, 1968

127) C.A. 72 : 107669f, 1970

128) J. Pharm. Pharmacol. 13 <7> : 396, 1961

129) 藥學雜誌 <日 > 89 <7> : 879, 1969

130) 醫學中央雜誌 <日 > 117 : 703, 1955

131) 中華生理學會第一屆會員代表大會會議論文摘要 < 藥> 78, 1956

132) C.A. 69 : 80126h, 1968

133) C.A. 61 : 1118f, 1964

134) C.A. 67 : 98735z, 1967

135) Nature 187 : 607, 1960

136) C.A. 68 : 113187p, 1968

137) 藥學硏究 <日 > 32 <8> : 36, 1960

138) 日本藥理學雜誌 56 : 97§ , 1960

139) 醫學中央雜誌 <日 > 235 : 299, 1968

140) 廣東中醫 <5> : 1, 1962

141) 藥學硏究 <日 > 22 <8∼ 9> : 352, 1950

142) 長家口醫傳 : 資料選編 21, 1972

143) C.A. 64 : 10122f, 1964

144) 中華醫學 50 <8> 524, 1964

145) 中國藥學會 1962年學術會議論文摘要 345, 1963

146) C.A. 52 : 13876f, 1958

147) 四川醫學院 : 中醫中藥硏究論文摘要選編 24, 1961

148) 科學通報 <12> : 379, 1958

149) 結核 <日 > 35 <6> : 446, 1960

150) Jap. J. Pharmacol. 18 : 353, 1968

151) 醫學中央雜誌 <日 > 192 : 193, 1963

152) 醫學中央雜誌 <日 > 121 : 652, 1956

153) C.A. 53 : 8433b, 1959

154) 內蒙古自治區成立十五周年醫學科學論文資料選集 34, 1962

155) C.A. 62 : 16819f, 1965

[臨床報道關聯文獻 ]

1) 中華內科 <3> : 226, 1960

2) 中華醫學 44 <5> 484, 1958

3) 中華醫學 44 <6> 464, 1960

4) 武漢醫藥衛生 1 <4> : 38, 1958

5) 武漢醫藥衛生 2 <3> : 272, 1959

6) 江西醫學院學報 <2> : 47, 1959

7) 中華醫學 46 <6> 460, 1960

8) 江蘇醫學會等 : 1962年年會論文選編 <上冊 > 101, 1963

9) 中華內科 5 <6> : 441, 1957

10) 武漢醫藥衛生 2 <2> : 145, 1959

11) 中華內科 11 <7> : 552, 1963

12) 福建中醫藥 3 <2> : 20, 1958

13) 福建中醫藥 3 <9> : 23, 1958

14) 中華內科 3 : 226, 1960

15) 中華醫學 42 <8> 655, 1956

16) 中華醫學 42 <7> 655, 1956

17) 中華醫學 42 <7> 669, 1956

18) 中華醫學 42 <8> 766, 1956

19) 中華醫學 42 <12> 1147, 1956

20) 長春醫學院學報 <1> 1956

21) 齊齊哈爾醫學院 : 論文 編 <1> : 7, 1960

22) 中華放射學 <4> : 299, 1956

23) 天津醫藥雜誌 1 <5> : 406, 1959

24) 中華婦産科 8 <3> : 封 2, 1960

25) 中華內科 7 <12> : 1169, 1959

26) 山東醫刊 <6> : 17, 1959

27) 遼寧醫學雜誌 <4> : 12, 1960

28) 人民保健 1 <3> : 235, 1959

29) 江西醫藥 5 <1> : 562, 1960

30) 中國醫學科學院陜西分院學報 <3> : 28, 1960

31) 中華醫學 <5> 486, 1958

32) 山東醫學科學院 : 1959年醫學科學硏究資料 編 <3> : 28, 1960

33) 江西醫學院學報 <2> : 51, 1959

34) 浙江中醫雜誌 <2> : 56, 1958

35) 人民保健 <5> : 432, 1959

36) 浙江中醫雜誌 <3> : 113, 1960

37) 浙江中醫雜誌 <6> : 299, 1958

38) 湖北·荊州衛生 <5> : 26, 1972

39) 湖南科技情報 <醫藥衛生 > <15> : 58, 1972

40) 中華外科 8 <4> : 354, 1960

41) 中華神經精神科 8 <1> : 42, 1964

42) 中華外科 7 <7> : 656, 1959

43) 遼寧醫學雜誌 <7> : 22, 1960

44) 遼寧醫學雜誌 2 <5> : 4, 1959

45) 貴陽市衛生局 : 醫藥科學硏究論文選集 <2> : 95, 1960

46) 安醫學報 <2 3> : 164, 1960

47) 中級醫刊 <2> : 113, 1966

48) 中華外科 13 <11> : 1006, 1965

49) 河北醫學院學報 <1> : 73, 1960

50) 藥學通報 <8> : 388, 1959

51) 中華眠科 9 <2> : 80, 1959

52) 中華外科 <10> : 1029, 1959

53) 中華神經精神科 5 <4> : 242, 1959

54) 江西醫學院學報 <2> : 41, 1959

55) 上海中醫藥雜誌 <8> : 22, 1964

56) 福建中醫藥 <4> : 44, 1965

 

성분 10)

한국명: 오가피            중문명 : 五加皮

영문명: Acanthopanex     라틴학명 : Acanthopanex

[根據藥典 ]

1) 本經

2) 科學的民間藥草

3) 雷公 炙論

4) 別錄

5) 本草圖經

6) 本草綱目

7) 草木便方

8) 藥性論

9) 醫林纂要

10) 四川中藥誌

11) 雷公 制藥性解

12) 本草經疏

13) 日華子本草

14) 本草再新

15) 陜西中草藥

16) 云南中草藥

17) 本草經集注

18) 得配本草

19) 瑞竹堂經驗方

20) 衛生家寶方

21) 外科大成

22) 保 撮要

23) 千金方

24) 局方

25) 驗方新編

26) 藥性類明

27) 本草求眞

28) 本草思辨錄

29) Hahn, D. R., et al. : Yakhak Hoeji 29, 357 (1985)

30) Kim, Y. H., Chung B.S., et al. : Kor. J. pharmacog, 16,   151 (1985)

31) Young Ho Kim, Bo Sup CHung et al. : Arch. Pharm. Res. 11(2),   159 (1988)

32) 정지연 , 한덕룡 : 약학회지 35, 240 (1991)

33) Jeung-Hee Kim,  Dug-Ryong Haln : Arch. Pharm. Res. 4, 59 (1981)

34) Dug-Hahn, Ryoji Kasai, et al. : Chem. Pharm. Bull, 32(3) 1244 (1984)

35) Ryoji-Kasai, et a;. : Chem Pharm. Bull. 34(8). 3284 (1986)

36) 한덕룡 외 : “인삼과 오가과 식물의 약리비교 (I)”

37) 韓德龍 , 金昌種 , 金貞姬 : 藥學會誌 29, 367 (1985)

38) 金昌種 , 韓德龍 : 藥學會誌 24, 123 (1980)

39) 노환성 외 : 생약학회지 21(2) 81 (1977)

40) Ji-Naang Fang et al. : Phytochem., 24, 2619 (1985)

41) H. Hikino, et al. : Journal of Natural produces, 49. 293 (1986)

[處方名例 ]

1) 五加皮散

2) 五加皮丸

3) 油煎散

4) 五加酒

5) 羚羊角湯

6) 五加皮脊湯

[成分關聯文獻 ]

1) 中草藥有效成分的硏究 <第 1分冊 > 382, 1972

2) C.A. 65 : 15790d, 1966

3) 醫學中央雜誌 <日 > 225 : 329, 1967

4) C.A. 63 : 843g, 1965

5) C.A. 64 : 8290a, 1966

6) 中草藥有效成分的提取和分離 252, 1972

7) Chem. Rev. 55 : 957, 1955

8) C.A. 65 : 2626h, 1966

9) C.A. 49 : 5603b, 1955

10) C.A. 70 : 112397m, 1969

11) C.A. 72 : 19118c, 1970

12) C.A. 62 : 11630a, 1965

13) C.A. 67 : 54394h, 1967

14) C.A. 71 : 81693u, 1969

15) C.A. 76 : 32224m, 1972

16) C.A. 70 : 112397m, 1969

17) C.A. 73 : 73823n, 1970

[藥理關聯文獻 ]

1) 中國生理科學會學術會議論文摘要 編 < 藥理> 118, 1964

2) 中國生理科學會學術會議論文摘要 編 < 藥理> 119, 1964

3) 中國醫學科學院 : 醫學參考資料 7 : 30, 1972

4) Ann. Rev. Pharmacol. 9 : 419, 1969

5) C.A. 55 : 9654d, 1961

6) C.A. 61 : 7550e, 1964

7) C.A. 59 : 14483f, 1963 ; 60 : 16389b, 1964

8) C.A. 61 : 1134g, 1964

9) 醫學中央雜誌 <日 > 228 : 715, 1967

10) C.A. 71 : 48128r, 1969

11) 醫學中央雜誌 <日 > 280 : 718, 1972

 

성분 11)

한국명: 산약               중문명 : 山藥

영문명: Dioscorea Root     라틴학명 : Dioscorea Japonica

[根據藥典 ]

1) 山海經

2) 本經

3) 吳普本草

4) 別錄

5) 兼名苑

6) 雜要訣

7) 淸異錄

8) 飮編新參

9) 浙江中藥手冊

10) 江蘇植藥誌

11) 廣西中藥誌

12) 四川中藥誌

13) 湖南藥物誌

14) 藥材學

15) 杭州藥植誌

16) 藥性類明

17) 藥品化義

18) 湯液本草

19) 得配本草

20) 藥性論

21) 食療本草

22) 日華子本草

23) 傷寒蘊要

24) 本草綱目

25) 本草經集注

26) 聖濟總錄

27) 瀕湖經驗方

28) 百一選方

29) 普濟方

30) 聖惠方

31) 儒門事親

32) 簡便單方

33) 救急易方

34) 本經逢原

35) 醫經遡 集

36) 本草正

37) 本草求眞

38) 本草經讀

39) 本經疏證

40) 唐本草

41) 本草圖經

42) 植物名實圖考

43) T. Hashimoto et al. : Planta Med. 108 <4> 369 (1972)

44) Idem. Agr. Biol. Chem. 35 <4> 619 (1971)

45) H. Hikino, et al. : Planta Medica 168 (1986)

46) T. Kiho, et al. : Chem. Pharm. Bull , 33, 270 (1985)

[處方名例 ]

1) 山芋丸

2) 秘元煎

3) 胃關煎

4) 壽脾煎

5) 右歸飮

6) 附益地黃飮

7) 固眞飮子

8) 蔘 白朮散

9) 六味地黃元

10) 古庵心腎湯

11) 增益歸茸丸

12) 丸仙王道

[成分關聯文獻 ]

1) 中草藥有效成分的硏究 <第 1分冊 > 435, 1972

2) C. A. 70 : 19021z, 1969

3) C. A. 68 : 36753r, 1968

4) C. A. 68 : 21025f, 1968

5) C. A. 64 : 18314g, 1966

6) C. A. 73 : 127768u, 1970

7) C. A. 69 : 10650a, 1968

8) C. A. 68 : 96970u, 1968

9) 藥學雜誌 <日 > 74 : 72, 1954

10) 藥學雜誌 <日 > 74 : 984, 1954

11) 中國藥學會 1962年學術會議論文文摘集 43, 1959

12) C. A. 82 : 125560g, 1975

13) C. A. 82 : 156636r, 1975

 

성분 12)

한국명: 구기자           중문명 : 枸杞子

영문명: Lycium Fruit     라틴학명 : Lycium Chinese

[根據藥典 ]

1) 本草經集注

2) 救荒本草

3) 藏府藥式補正

4) 河南中藥手冊

5) 江蘇植藥誌

6) 河北藥材

7) 山西中藥誌

8) 中藥材手冊

9) 四川中藥誌

10) 藥材學

11) 本經

12) 詩經

13) 毛詩傳

14) 吳普本草

15) 廣雅

16) 拘朴子

17) 別錄

18) 日華子本草

19) 本草衍義

20) 草木便方

21) 藥性論

22) 食療本草

23) 本草 言

24) 本草經解

25) 要藥分劑

26) 本草述

27) 本草經疏

28) 本草逢原

29) 本草撮要

30) 醫級

31) 古今錄驗方

32) 瑞竹堂經驗方

33) 延年方

34) 聖惠方

35) 撮生秘剖

36) 撮生從妙方

37) 本草綱目

38) 保壽堂方

39) 本草通玄

40) 本草求眞

41) 本草正

42) 重慶堂隨筆

43) 夢溪筆談

44) Sannai, Akiyoshi et al. : Agric. Biol. Chem. 47 <10>, 2379 (1983)

45) Qi, zongshao et al. : Ningxia Daxue Xuebao, Ziran Kexueban. <1> 67 (1981)

46) Muraviev M.A. et al. : Farmatsiya 32 <1>, 17 (1983)

47) Ahmad, Vigar Uddin et al. : J. Chem. Soc. Pak . 2 <3>, 113 (1980)

48) Sannai Akiyoshi et al. : Phytochem. 21 <12>, 2986 (1982)

49) Nishiyama, Ryuzo et al. : Nippon Nogei Kagaku Kaishi 43 <4>, 202 (1969)

50) Haensel, R. et al. : Arch. Pharm. 308 <8>, 653 (1975)

51) Haensel, R. et al. : Arch. Pharm. 310 <1>, 35 (1977)

52) Haensel, R. et al. : Arch. Pharm. 310 <1>, 38 (1977)

53) Sannai, Akiyoshi et al. : Agric. Biol. Chem . 48 <6> 1629 (1984)

54) Cabrera, J. L. et al. : An. Asoc. Quim. Argent. 69 <6>, 357 (1981)

55) Harsh, M. L. et al. : Curr. Sci. 50 <5>, 235 (1981)

56) Nishiyama R. et al. : Nogeikagaku Kaishi 43 <4>, 197 (1969)

57) Osawa, Shogo : Nigata Igakkai Zasshi 83 <2>, 82 (1969)

58) Funayama, Shinji et al. : Tetrahedron Lett . 21 <14>, 1355 (1980)

: Noguchi, Mamoru et al. : Chem. Pharm, Bull. 32, 3584 (1984)

[處方名例 ]

1) 枸杞丸

2) 枸杞子散

3) 煖肝煎

4) 滋陰大補丸

5) 滋陰陽血湯

6) 四神丸

7) 還少丹

[成分關聯文獻 ]

1) 徐國鈞 : 藥材學 513, 1963

2) 醫學中央雜誌 <日 > 226 : 223, 1967

3) 藥學硏究 <日 > 35 : 417, 1963

4) C.A. 69 : 25079v, 1968

[藥理關聯文獻 ]

1) 中國生理科學會學術會議論文摘要 編 < 藥理> 123, 1964

2) 藥學硏究 <日 >  34 <4> : 274, 1962

3) 日本藥理學雜誌 57 : 105§ , 1961

4) 醫學中央雜誌 <日 > 180 : 335, 1962

5) 藥學硏究 <日 >  34 <8> : 548, 1960

6) 日本藥理學雜誌 56 <4> : 151 §, 1960

7) A Manual of Pharmacology <Sollmann, T.> 8Ed. 414, 1957

8) C.A. 64 : 20530b, 1965

 

성분 13)

한국명: 대추               중문명 : 大棗

영문명: Jujube Fruit        라틴학명 : Zizyphus Jujube Milles

[根據藥典 ]

1) 別錄

2) 醫學入門

3) 詩經

4) 本經

5) 千金·食治

6) 本草綱目

7) 本草經疏

8) 本草經集注

9) 藥對

10) 日華子本草

11) 珍珠囊

12) 藥品化義

13) 本草再新

14) 中國藥植圖鑑

15) 本草 言

16) 隨息居飮食譜

17) 醫學衷中參西錄

18) 醒園錄

19) 聖濟總錄

20) 金 要略

21) 必效方

22) 千金方

23) 三因方

24) 海上方

25) 上海中醫藥

26) 註解傷寒論

27) 本經逢原

28) 長沙藥解

29) 友田正司 등 : 生藥 35, 194, (1981)

30) N. Okayama et al. : Chem. Pharm. Bull. 29, 3507 (1981)

31) Yagi, A., et al. : Chem. Pharm. Bull. 26, 1798, 3075 (1978)

32) 八木晟 등 : 藥學雜誌 , 101, 700 (1981)

33) Cyong, J. C., et al. : Chem. Pharm. Bull. 19, 2747 (1980) : 21, 1871 (1982)

[處方名例 ]

1) 大棗湯

2) 十棗湯

3) 棗蔘湯

4) 益脾餠

5) 甘來大棗湯

6) 大棗平胃散

7) 補益大棗粥

8) 棗子綠礬丸

[成分關聯文獻 ]

1) 中草藥有效成分的硏究 <第 1分冊 > 427, 1972

2) 中藥誌 2 : 28, 1959

[藥理關聯文獻 ]

1) 廣東中醫 <5> : 1, 1962

[臨床報道關聯文獻 ]

1) 浙江醫學 <創刊號 > : 44, 1960

2) 廣西醫學院 : 新醫藥傳刊 <2> : 11, 1972

The Therapeutics Of ELEOTIN: References

1. “Adult-Onset Diabetes Show Atherogenic Lipid Patterns.” Medical World News. P56, January 8, 1979.

2. Aguilar-Bryan, L., Nichols, C.G., Wechsler, S.W., Clement, J.P., Boyd, A.E., Gonzalez, G., Herrera-Sosa, H.,
Nguy, K., Bryan, J., and Nelson, D.A., Cloning of the ß-cell high-affinity sulfonylurea receptor: a regulator of
insulin secretion. Science 268:423- 426, 1995.

3. American Diabetes Association, American Diabetes Association Complete Guide to Diabetes.
Bantam, NY, 1996.

4. Anderson, J.W., et al., “Beneficial Effects of a High Carbohydrate, High Fiber Diet on Hyperglycemic
Diabetic Men.” American Journal of Clinical Nutrition 29:895-899, 1976.

5. Anon, Health Foods Business 38(8):13, 1992.

6. Awang, D.V.C., Canadian Pharmaceutical Journal 123: 121-126, 1990.

7. Bamford, D.S., Percival, R.C., and Tothill, A.U., British Journal of Pharmacology 40:161P-162P, 1970.

8. Barber, A.J., Pharmaceutical Journal 240:723-725, 1988.

9. Baskaran, K., et al., Antidiabetic Effect of a Leaf Extract from Gymnema sylverstre in
Non-Insulin Dependent Diabetes Mellitus Patients. J Ethnopharmacol 30:295-305, 1990.

10. Beckett, A.H., Belthle, F.W., Fell, K.R., and Lockett, M.F., Journal of Pharmacy and Pharmacology
6:785-796, 1954.

11. Biometric Society, “Report of the Committee for Assessment of Biometric Aspects of Controlled Trials of
the Hypoglycemic Agents.” Journal of the American Medical Association 231:583-608, 1975.

12. Blumenthal, M., Health Foods Business 35(9):18, 104-105, 1989.

13. Bosco, D., The People’s Guide to Vitamins and Minerals. Contemporary Books, Chicago, 1980.

14. Bricklin, M., Encyclopedia of Natural Home Remedies. Rodale Press, Emmaus, Pennsylvania,
pp.379-381, 1982.

15. Briggs, C.J., Canadian Pharmaceutical Journal 119:248-254,1986.

16. Bundesanzeiger (Cologne, Germany), May 15, 1985.

17. Bundesanzeiger (Cologne, Germany), January 5, 1989.

18. Burton, J., Lydia Pinkham is Her Name, Farrar, Straus, NY, p.107, 1949.

19. Calvert, G.D., Medical World News, p56, January 8, 1979.

20. Campbell, P., et al., “Pathogenesis of the Dawn Phenomenon in Patients with Insulin-Dependent Diabetes
Mellitus.” New England Journal of Medicine 312:1473-1479, 1985.

21. Castleman, M., The Healing Herbs. Rodale Press, Emmaus, Pennsylvania, 1991, pp.294-296.

22. Chakravarthy B.K, Gupa S., and Gode K.D., Functional ß-Cell Regeneration in the Islets of Pancreas
in Alloxan Induced Diabetic Rats by (-)-Epicatechin. Life Sci 31:2693-2697, 1982.

23. Chakravarthy B.K., et al., Pancreatic ß-Cell Regeneration in Rats by (-)-Epicatechin. Lancet 2:759-760,
1981.

24. Chalmers, T.C., ed., “Settling the UGDE Controversy.” Journal of the American Medical Association 231:
624-625, 1975.

25. Colata, G., “How Important is Dietary Calcium in Preventing Osteoporosis.” Science 233:519-520, 1986.

26. Cooper, W.D., “Cardiac Arrhythmias Following Acute Myocardial Infarction: Associations with the Serum
Potassium Level and Prior Diuretic Therapy.” European Heart Journal 5:464, 1984.

27. Cornfield, J., “The University Group Diabetes Program: A Further Study of the Mortality Finding.” Journal of
the American Medical Association 217:1676-1687, 1971.

28. Coustan, D.R., “A Randomized Clinical Trial of the Insulin Pump vs. Intensive Conventional Therapy in
Diabetic Pregnancies.” Journal of the American Medical Association 255:631-636, 1986.

29. Cryer, P.E., “Glucose Counterregulation, Hypoglycemia, and Intensive Insulin Therapy in Diabetes Mellitus.”
New England Journal of Medicine 313:232-241, 1985.

30. Davidson, J., Clinical Diabetes Mellitus, A Problem Oriented Approach. Thieme, Inc., NY, 1986.

31. Davidson, J.K., “The FDA and Hypoglycemic Drugs.” Journal of the American Medical Association
232:854, 1975.

32. Davidson, M.B., Diabetes Mellitus, Diagnosis and Treatment, 2nd ed., John Wiley & Sons, NY, 1986.

33. De Smet, P.A.G.M., Canadian Pharmaceutical Journal 124:5,1991.

34. “Diabetes Diagnoses Grounded on GTT Are Wrong Most of Time.” Family Practice News: 1, October 15
1979.

35. Duker, E.-M., Kopanski, L., Jarry, H., and Wuttke, W., Planta Medica 57:420-424, 1991.

36. Dupree, J., “Near Normal Glycemic Control Does Not Slow Progression of Mild Diabetic Retinopathy.”
Paper presented to American Diabetes Association meeting, 1983.

37. Earon, G., Stern, E., and Lavosky, H., Successful Use of Atriplex halimus in the Treatment of Type II
Diabetic Patients. Controlled clinical research report on the subject of Atriplex. Unpublished study
conducted at the Hebrew University of Jerusalem, Jerusalem, Israel, 1989.

38. “Fish Oil May Ease Arthritis Pain.” Medical World News. July 14, 1986, p.9. General Practitioner Research
Group, “Calcium Pantothenate in Arthritic Conditions.” Practitioner 224:208, 1980.

39. Gonzalez, E.R., “Exercise Therapy Rediscovered for Diabetes, But What Does It Do?” Journal of the
American Medical Association 242:1591, 1979.

40. Goo, A.K., Carson, D.S., and Bjelajac, A., Metformin: a new treatment option for non-insulin-dependent
diabetes mellitus. Journal of Family Practice 42:612-618, 1996.

41. Greene, E-L., “Well-Being Up With Captopril, Down With Two Other Agents.” Medical Tribune, p8,
September 17, 1986.

42. Hadden, D.R., “Myocardial Infarction in Maturity-Onset Diabetes, A Retrospective Study.” Lancet
1:335-338, 1972.

43. Hansel, R., Phytopharmaka, 2nd ed., Springer-Verlag, Berlin, 1991, pp.223-230.

44. Hendler, S.S., The Complete Guide of Anti-Aging Nutrients. Simon & Schuster, NY, 1985

45. Himsworth, H.P., “The Dietetic Factor Determining the Glucose Tolerance and Sensitivity to Insulin of
Healthy Men.” Clinical Science 2:67-94, 1935.

46. Howes, L.G., Sundaresan, P., Lykos, D., Cardiovascular effects of oral hypoglycemic drugs. Clin. Exp.
Pharm. Physiol. 23(3):201-206, 1966.

47. Johnson, N.E., “Effect of Level of Protein Intake of Urinary and Fecal Calcium and Calcium Retention of
Young Adult Males.” Journal of Nutrition 100:1425-1430, 1970.

48. Kang, S.M., Traditional Korean Herbal Treatment for Diabetes. Hyungsul, Seoul, Korea, 1990

49. Kempner, W., “Treatment of Hypertension Vascular Disease with Rice Diet.” American Journal of
Medicine 4:545-577, 1948.

50. Keye, W.R., Jr., “Premenstrual Syndrome (PMS)” in Conn’s Current Therapy, H.F., Conn and R.E. Rakel,
eds., W.B. Saunders, Philadelphia, 1984, pp.1000-1003.

51. Khoo, S.K., Munro, C., and Battistutta, D., Medical Journal of Australia 153:189-192, 1990.

52. Kim, E.J., Choi, M.G., et al., Encyclopedic Knowledge on Diabetes,153
Questions and Answers. Seoeum, Seoul, Korea, 1995.

53. Klachko, D.M., et al., “Blood Glucose Levels During Walking in Normal and Diabetic Subjects.” Diabetes
21:89-100, 1972.

54. Knatterud, G.L., et al., “Hypoglycemic Agents on Vascular Complications in Patients with Adult-Onset
Diabetes.” Journal of the American Medical Association 240: 37-42, 1978.

55. Koto, Y., New Treatment for Diabetes, Medical Journal, Osaka, Japan, 1994.

56. Kuller, L.H., “Unexpected Effects of Treating Hypertension in Men with Electrocardiographic Abnormalities:
A Critical Analysis.” Circulation 73:114-123, 1986.

57. Lauritzen, T., “Two-Year Experience with Continuous Subcutaneous Insulin Infusion in Relation to
Retinopathy and Neuropathy.” Diabetes 34 [suppl.3]:74-79, 1985.

58. Lawrence Review of Natural Products, March 1989.

59. Lehmann-Willenbrock, E., and Riedel, H.H., Zentralblatt fur Gynakologie 110:611-618 1988.

60. Lernmark, A., “Islet Cell Surface Antibodies in Juvenile Diabetes Mellitus.” New England Journal of
Medicine 299:375-380, 1978.

61. Leslie, R.D.G., ed., Cause of Diabetes, Genetic and Environmental Factors. John Wiley & Sons, West
Sussex, England, 1993.

62. Levey, Gerald S., and Roger F. Palmer, “Effect of Tolbutamide on Adenyl Cyclase in Rabbit and Human
Heart and Contractility of Isolated Rabbit Atria.” Journal of Clinical Endocrinology 33:317-334, 1971.

63. Lorenzi, Mara, and Michael Goldman, “Improved Diabetic Control and Retinopathy.” New England Journal
of Medicine 308:1600, 1983.

64. Lubbos, H., Miller, J.L., and Rose, L.I., Oral hypoglycemic agents in type II diabetes mellitus. American
Family Physician . 52:2075-2078, 1995.

65. Mada, Z., et al., Glucose-Lowering Effect of Fenugreek in Non-Insulin Dependent Diabetics.
Eur J Clin Nutr 42:51-54, 1988.

66. Mather, H.M., “Hypomagnesaemis in Diabetes.” Acta Clinica Chemica 95:235-242, 1979.

67. Mazess, R.B., “Bone Mineral Content of North Alaskan Eskimos.” American Journal of Clinical Nutrition
27:916-925, 1974.

68. McDougall, J., McDougall’s Medicine, A Challenging Second Opinion. New Century Press, Piscataway,
New Jersey, 1985.

69. Medical World News, p9, July 14, 1986.

70. Merrimee, Thomas, et al., “Insulin Like Growth Factors, Studies in Diabetes With and Without Retinopathy.”
New England Journal of Medicine 309:527-530, 1983.

71. Mertz, W., “Effects and Metabolism of Glucose Tolerance Factor.” Nutrition Review 33:1929, 1975.

72. Miranda, Perla M., and David L. Horwitz, “High-Fiber Diets in the Treatment of Diabetes Mellitus.”
Annals of Internal Medicine 88:482-486, 1978.

73. Mitch, William E., et al., “The Effects of a Keto Acid-Amino Acid Supplement to a Restricted Diet on the
Progression of Chronic Renal Failure.” New England Journal of Medicine 311:623-629, 1984.

74. Morgan, T.O., “Failure of Therapy to Improve Prognosis in Elderly Males with Hypertension.” Australia
Medical Journal 2:27, 1980.

75. Murray, M.T., Diabetes and Hypoglycemia, How You Can Benefit from Diet, Vitamins, Minerals, Herbs,
Exercise and Other Natural Methods. Prima, Rocklin, CA, 1994.

76. Murray, M.T., The Healing Power of Herbs, The Enlightened Persons’s Guide to the Wonders of Medicinal
Plants, Rev.2nd ed., Prima, Rocklin, CA, 1995.

77. Nelson, R., “Dysmenorrhea” in Conn’s Current Therapy, H.F. Conn and R.E. Rakel, eds. W.B. Saunders,
Philadelphia, pp.999-1000, 1984.

78. Nutrition Search, Inc., Nutrition Almanac. McGraw-Hill Paperbacks, NY, 1979.

79. Parham, B., “What’s Wrong with Eating Meat?” Ananda Marga Publications, Denver, 1981.

80. Peterson, L., Cardiovascular Rehabilitation: A Comprehensive Approach. Macmillan, NY, 1983.

81. Phillipson, B.E., et al., “Reduction of Plasma Lipids, Lipoproteins, and Apoproteins by Dietary Fish Oils in
Patients with Hypertriglyceridemia.” New England Journal of Medicine 312:1210-1216, 1985.

82. Pogatsa, G. Potassium channels in the cardiovascular system. diabetes Res. Clin. Practice. 28:591-589,
1995.

83. Rabinowitch, I.M., “Effects of the High Carbohydrate-Low Calorie Diet Upon Carbohydrate Tolerance in
Diabetes Mellitus.” Canadian Medical Association Journal 33:136-144, 1935.

84. Rabinowitch, I.M., “Experiences with a High Carbohydrate-Low Calorie Diet for the Treatment of Diabetes
Mellitus.” Canadian Medical Association Journal 23:489-498, 1930.

85. Rabinowitch, I.M., “The Present Status of the High Carbohydrate-Low Calorie Diet for the Treatment of
Diabetes.” Canadian Medical Association Journal 26:141-148, 1932.

86. Ribes, G., et al., Effects of Fenugreek Seeds on Endocrine Pancreatic Secretions in Dogs. Ann Nutr
Metab 28: 37-43, 1984.

87. Roberts, H.J., “Perspective on Vitamin E as Therapy.” Journal of the American Medical Association
256:129, 1981.

88. Rose, W.C., “Amino Acid Requirements of Man.” Journal of Biological Chemistry 217:997-1004, 1955.

89. Rudman, D., “Megadose Vitamins. Use and Misuse (editorial).” New England Journal of Medicine
309:488, 1983.

90. Sackler, A.M., “On the Nonsense of Official Recommended Daily Allowances (RDAs).” Medical Tribune,
p46, September 18, 1985.

91. Sahelian, R., DHEA, A Practical Guide. Avery Publishing Group, NY, 1996.

92. Samsum, W.D., “The Use of High Carbohydrate Diets in the Treatment of Diabetes Mellitus.” Journal of the
American Medical Association 86:178-181, January 16, 1926.

93. Saudek, C.D., Rubin, R.R., and Shump, C.S., The Johns Hopkins Guide to Diabetes for Today and
Tomorrow. The Johns Hopkins University Press, Baltimore, 1997.

94. Saw, D., Pitman, E., Maung, M., Savasatit, P., Wasserman, D., Yeung, C.K.,1996. Granulomatous hepatitis
associated with glyburide. Digestive Dis. Sci.41(2):322-315.

95. Schaumburg, H., “Sensory Neuropathy from Pyridoxine Abuse.” New England Journal of Medicine
309:1445-1448, 1983.

96. Schor, S., “The University Group Diabetes Program, A Statistician Looks at the Mortality Results.” Journal
of the American Medical Association 217:1671-1675, 1971.

97. Seifter, Eli, Ph.D., et al., “Impaired Wound Healing in Streptozotic Diabetes: Prevention by Supplementary
Vitamin A.” Annals of Surgery 194:42-50, 1982.

98. Seo, J.S., and Yoo, D.J., Encyclopedic Knowledge on Adult Disease, 505 Questions and Answers.
Seoeum, Seoul, Korea,1996.

99. Shanmugasundaram, E.R.B., et al., Use of Gymnema sylverstre Leaf Extract in the Control of Blood
Glucose in Insulin-Dependent Diabetes Mellitus. J Ethnopharmacol 30:281-294, 1990.

100. Sharma, K.K., et al., Antihyperglycemic Effect of Onion: Effect on Fasting Blood Sugar and Induced
Hyperglycemia in Man. Indian J Med Res 65:422-429, 1977.

101. Sharma, R.D., Raghuram T.C., and Rao N.S., Effect of Fenugreek Seeds on Blood Glucose and Serum
Lipids in Type I Diabetes. Eur J Clin Nutr 44:301-306, 1990.

102. Sharpe, G.R., and Farr, P.M., Lancet 335:1283,1990.

103. Sheela, C.G., and Augusti K.T., Antidiabetic Effects of S-Allyl Cysteine Sulphoxide Isolated from Garlic
(Allium sativum Linn.). Indian J. Exp Biol 30:523-526, 1992.

104. Somogyi, M., Bulletin of the St. Louis Jewish Hospital Medical Staff, May 1951.

105. Somogyi, M., “Dietary and Insulin Therapy of Diabetes.” Bulletin of the St. Louis Jewish Hospital Medical
Staff:1-16, October 1949.

106. Srikanta, S., “Islet-Cell Antibodies and BETA-Cell Function in Monozygotic Triplets and Twins Initially
Discordant for Type I Diabetes Mellitus.” New England Journal of Medicine 308:322-325, 1983.

107. Srivastava, Y., et al., Antidiabetic and Adaptogenic Properties of Momordica charantia Extract:
An Experimental and Clinical Evaluation. Phytother Res 7:285-289, 1993.

108. Stern, E., Successful Use of Atriplex halimus in the Treatment of Type II Diabetic Patients. A preliminary
study. Unpublished study conducted at the Zamenhoff Medical Center, Tel Aviv, Israel, 1989.

109. Strobl, J., and Thomas, J.A., “Chapter 66” in Modern Pharmacology, 3rd ed,. C.R. Craig and R.E. Stitzel,
eds., Little, Brown, Boston, pp.882-884, 1990.

110. Struthers, A.D., “Prior Thiazide Diuretic Treatment Increases Adrenaline-Induced Hypokalemia.” Lancet
1:1358, 1985.

111. Sweeney, J.S., “Dietary Factors That Influence the Dextrose Tolerance Test.” Archives of Internal
Medicine 40:818-830, 1927.

112. Tan, G.H., and Nelson, R.L., Pharmacologic treatment options for non-insulin- dependent diabetes
mellitus. Mayo Clinic Proceedings 71:763-768, 1996.

113. The Extra Pharmacopoeia-Martindale, 24th ed., vol.1, The Pharmaceutical Press, London, p.614, 1958.

114. The Kroc Collaborative Study Group, “Blood Glucose and the Evolution of Diabetic Retinopathy and the
Albuminuria.” New England Journal of Medicine 311:1365-1372, 1984.

115. The Kroc Collaborative Study Group, “Hopes for Whole Pancreas, Islet Cell Transplant Falter.” Internal
Medicine News, September 1-14, 1986.

116. Thomas, J.A., “Chapter 63” in Modern Pharmacology, 3rd ed., C.R. Craig and R.E. Stitzel, eds., Little,
Brown, Boston, p.850, 1990.

117. “Tight Control Trial Needs More Diabetics.” Medical World News, p6, February 23, 1987.

118. Tyler, V.E., Herbs of Choice, The Therapeutic Use of Phytomedicinals. Pharmaceutical Products Press,
Binghamton, NY, 1994.

119. “University Group Diabetes Program: A Study of the Effects of Hypoglycemic Agents on Vascular
Complications in Patients with Adult-Onset Diabetes. 11. Mortality Results.” Diabetes 19 [Suppl.]:814,
1970.

120. “University Group Diabetes Program.” Journal of the American Medical Association 218:1400-1410,
1971.

121. Walker, R., “Calcium Retention in the Adult Human Male As Affected by Protein  Intake.” Journal of
Nutrition 102:1297-1302, 1972.

122. Warmer, Rebecca, et al., Off Diabetes Pills, A Diabetic’s Guide to Longer Life. Public Citizens’ Health
Group, Washington, 1978.

123. Watanabe, Y., et a.:Chem. Pharm. Bull., 32, 3994, 1984: Shoji, K., et al.: ibid. 20, 1729, 1972:21, 308,
1973: 25, 3049, 1977

124. Weiss, R.F., Herbal Medicine. AB Arcanum, Gothenburg, Sweden, pp.275-278, 1988.

125. Welihinda, J., et al., Effect of Momardica charantia on the Glucose Tolerance in Maturity Onset Diabetes.
J Ethnopharmacol 17:277-282, 1986.

126. Welihinda, J., et al., The Insulin-Releasing Activity of the Tropical Plant Momordica charantia. Acta Biol
Med Germ 41:1229-1240, 1982.

127. Whitaker, J.M., Reversing Diabetes. Warner Books, NY, 1987.

128. Winterhoff, H., Gorkow, C., and Behr, B., Zeitschrift fur Phytotherapie12:175-179, 1991.

129. Woongjin Health Book 2, Diabetes. Woongjin, Seoul, Korea, 1997.

130. Yamahara, J., et al: Yakugaku zasshi, 101, 86,1973.

131. Yoon, J.W., “Isolation of a Virus from the Pancreas of a Child with Ketocidosis.” New England Journal of
Medicine 300:1173-1179, 1979

The Therapeutics Of ELEOTIN : 5.0. SUMMARY

ELEOTIN is a new herbal combination treatment of Type II diabetes, also known as non-insulin-dependent diabetes mellitus (NIDDM). ELEOTIN comprises several medicinal plants proved effective in reducing blood glucose levels in diabetic animals. ELEOTIN also proved effective in restoring the general health of diabetic patients. The possible mechanism of action of the composition involves a combination of

 

1) Increased expression of insulin receptors in hepatocytes and skeletal muscles,

2) Increased insulin secretion in pancreatic ß-cells,

3) Inhibition of alpha-glucohydrolase activity,

4) Increase in the levels of the GLUT (glucose transporter) 2 protein in pancreatic ß-cells.

ELEOTIN also proved effective in reducing blood glucose levels and restoring the general health of diabetic humans.

Therapeutic implications of the above findings are:

1) ELEOTIN seems to be a strong candidate for both a short-term and long-term treatment of NIDDM.

2) ELEOTIN is safe for a long-term use due to its non-toxicity and a combination approach.

3) ELEOTIIN seems to provide safeguards against occasional hypoglycemia.

4) ELEOTIN seems to be not only compatible with but also supportive of other diabetes-related treatment such as insulin injection and oral hypoglycemic agents.

5) ELEOTIN does not seem to develop any resistance with long-term usage.

The Therapeutics Of ELEOTIN : 4.0. How to Use ELEOTIN

4.1. How Does ELEOTIN Provide a Balanced Therapy?

4.1.1. Usage

ELEOTIN is composed of three different herbal plant combinations which work together synergistically to provide an overall balanced treatment. Each formula is taken at a different time of the day to provide maximum and total benefit.

Formula
Direction
Purpose
A
30 minutes before meals
Lowers the blood glucose level after meals by stimulating insulin secretion
B
On an empty stomach
Strengthens the function of insulin receptors
C
Before bedtime
Creates and strengthens ß-cells

ELEOTIN is to be consumed as a supplement to your regular diet. To benefit fully from ELEOTIN, Eastwood recommends that you observe a regime that includes a well-balanced diet and low fat, high fibre foods, regular exercise and abstention from alcohol. It is important to follow the directions for use carefully and take each formula at the appropriate time to achieve the best results.

The importance of diet, exercise, and stress management cannot be overly emphasised in the successful management of diabetes type II even when ELEOTIN is administered. Diet, exercise, and stress, as well as genetic, environmental, and psychological factors may offer possible explanations for the variation that exists among diabetes type II patients in response to ELEOTIN administration. Differences in the genetic make-up among diabetics results in different physiological conditions at the cellular and molecular level, such as different rates of insulin receptor up-regulation and different levels of insulin secretion, insulin synthesis, and GLUT2 protein synthesis.

4.1.2. Cautions

It is obvious that a diabetic patient should not stop taking hypoglycemic drugs until his blood glucose level reduces and fully stabilizes due to ELEOTIN’s effects. We can not emphasize too strongly the danger of premature discontinuance of other diabetic treatments when ELEOTIN is administered. The danger of premature discontinuance of other diabetic treatment is all the more serious because patients who begin to feel remarkable improvement of general health conditions are easily tempted to discontinue chemically based hypoglycemic drugs.

According to our experience, patients often misinterpret the general improvement of health for the sign of being cured of diabetes as ELEOTIN users experience the general health improvement prior to the cure of diabetes itself. Diabetes is a serious disease. Patients should use common sense. They should not stop effective treatments just because they feel well for some time.

However, there are also not so infrequent cases where patients experience hypoglycemia because they continue to take other hypoglycemic agents even after ELEOTIN’s curative effects helped the body to naturally reduce and stabilize the blood glucose levels. In that case, hypoglycemic drugs simply overkill. Clearly, ELEOTIN does not cause hypoglycemia. ELEOTIN just normalizes blood glucose levels, while hypoglycemic agents further push down blood glucose levels, causing hypoglycemia. In fact, ELEOTIN’s up-regulation of insulin receptors is an effective defensive mechanism against potential hypoglycemia caused by excessive secretion of insulin-stimulated by chemical hypoglycemic agents especially such as sulfonylurea. So, regular monitoring and regular consulting with the physicians are always needed.

People who have suffered diabetes for a long time, and heard about remarkably encouraging results of ELEOTIN tend to be so impatient to experience the benefits that they often overdose themselves with needlessly excessive amounts of ELEOTIN, expecting quicker and stronger results. Of course, ELEOTIN itself is quite safe even when consumed in substantial quantities.

However, drinking too much water with ELEOTIN from time to time creates emergency situations for those people with serious urination problems from kidney failure. Even though these patients can experience remarkable improvement of this urination problem in the long run when they slowly increase the ELEOTIN consumption, they should start with a very small quantity such as 1 gram per serving. If the daily water intake is limited, they can start the ELEOTIN treatment without any preparation. They can just take small quantity of the powder itself until the urination function is improved. Recovery of urination functions and improvements of kidney health are the most common testimonies of ELEOTIN users.

We strongly recommend the patient to take prudent and moderate approach toward ELEOTIN treatment. Also, as ELEOTIN is not an inexpensive treatment anyhow due to the scarcity of material and difficulty of quality control, there are little benefits to gain from the excessive consumption. Another reason for moderate use of ELEOTIN is that one of the fundamental philosophy behind the working of ELEOTIN prescribe a combinatorial, thus mild approach toward this chronic disease. Excessive consumption may defeat the basic spirit of such a synergistic approach even though no harmful consequences will result. What body needs is a correct signal, not a strong signal. We do not push the button for a higher floor harder. We just push the right button. We invite the users to take a prudent and moderate approach.

4.2. Preparation for All 3 Formulas

4.2.1. Stove Top or Slow Cook

  1. Open one 8-gram pouch and pour into 360 ml (1-1/2 cups) of water.
  2. Cook on low heat for 1 to 2 hours until reduced by half.
  3. Do not boil.
  4. Sediment is drinkable but in rare cases may produce stomach upset. If so, drink liquid only, or reduce quantity.
  5. If you are unaccustomed to herbal products, you may start with a smaller quantity, such as 4 grams (1/2 pouch), and increase gradually.
  6. You may prepare 2 to 3 servings at one time. Store in a tightly sealed bottle and refrigerate.
  7. Drink warm.

 

4.2.2. Alternative Preparations

Separate preparation described above surely means substantial inconvenience. Eastwood found that users who mix all three and treat them as one formula still enjoy many of the desirable effects of ELEOTIN.

However, there seems to be some sacrifice in the speed at which the beneficial power of ELEOTIN takes full effect. In extreme case, some users who mix all three formulas then simply consume the powder directly without any further preparation, still experience quite impressive results.

However, Eastwood believes that some ingredients and nutrients should be heated for an adequate amount of time in order to be extracted from the fibers in which the ingredients are embedded so that informs optimal digestion and absorption can be attained. Also, we found that the effects of ELEOTIN stayed almost intact when prepared with Microwave ovens like

(1) Open one 8-gram pouch and pour into 200 ml (3/4 cup) of water.

(2) Cook 10 to 20 minutes with medium to low heat until volume is 180 ml.

(3) Do not boil. Do not overflow.

(4) Sediment is drinkable but in rare cases may produce stomach upset. If so, drink liquid only,
or reduce quantity.

(5) If you are unaccustomed to herbal products, you may start with a smaller quantity,
such as 4 grams (1/2 pouch), and increase gradually.

(6) You may prepare 2 to 3 servings at one time. Store in a tightly sealed bottle and refrigerate.

(7) Drink warm.

We found that when ELEOTIN is prepared with higher heat, the taste often becomes somewhat bitter. We recommend a slow simmering like preparation rather than a quick boiling. Eastwood is currently working on making ELEOTIN in a convenient tablet form, and testing whether the efficacy and the safety will stay the same. A more convenient form of ELEOTIN will be available for consumers in the near future, however it may be slightly more expensive.

4.3. How Long Does It Take to Benefit from ELEOTIN?

Treatment with ELEOTIN results in lower levels of blood glucose, and following termination of treatment these blood glucose levels remain low.

The beneficial effects of ELEOTIN are apparent within a period of 3 to 12 months and ELEOTIN continues to demonstrate beneficial effects for the duration of the treatment period.

Type of patient
When you will experience beneficial effects
 
When you will be able to reduce your daily consumption of ELEOTIN
Patient with mild symptoms7
Approximately 3 months 
Approximately 6 months 
Patient with severe symptoms8
Approximately 6 months 
Approximately 1 to 2 years 
Patient with impaired function of ß-cells
6 months to 1 year 
Several years

ELEOTIN does not affect diabetes type II patients in a uniform manner. Genetic factors and environmental factors, such as diet and exercise, may vary the response of individuals to ELEOTIN.

The Therapeutics Of ELEOTIN : 3.0. Comparison of ELEOTIN with Other Treatments

3.1. Comparison of ELEOTIN with Chemical Hypoglycaemic Agents

ELEOTIN has a few advantages and disadvantages compared with available oral chemical drugs.

3.1.1. Advantages of ELEOTIN

The advantages of ELEOTIN in comparison with oral chemical hypoglycemic agents are as follows.

At first, ELEOTIN does not have any adverse side effects while most of oral hypoglycemic agents have. (For more details, see Appendix 1)

Secondly, ELEOTIN does not develop any resistance, while most chemical hypoglycemic agents do. In other words, the effect of ELEOTIN does not diminish even when one uses ELEOTIN for a long time.

Thirdly, ELEOTIN is safe for long term use or for the consumption of large quantity, while other chemical hypoglycemic agents often creates fatal consequences when taken in large quantities, unsuitable for long term use.

Fourthly, the beneficial effects of ELEOTIN seem to last for substantial periods, often as long as years after the termination of the usage, while chemical agents have only temporary effects on the control of blood glucose levels.

Fifthly, ELEOTIN seems to bring about the improvement of general health conditions for its users. Even though the general health promotion effects of ELEOTIN is hard to quantify, most of users report less fatigue, improved sleeping, better skin conditions, improved memory, and so on. No chemical agents bring about these benefits.

3.1.2. Disadvantages of ELEOTIN

There are certain disadvantages of ELEOTIN in comparison with other oral hypoglycemic agents.

Firstly, ELEOTIN’s active ingredients are not yet known and they will be difficult to isolate in the near future. Considering that there are usually more than 200 secondary metabolites in a plant, and there are more than ten herbs and plants in the composition of ELEOTIN the possible combinations of active ingredients in ELEOTIN are of almost an infinite number. Even so, Eastwood believes they have a few strong candidates as to the primary active ingredients – a few versions of flavonoids and a few types of potassium salts.

Unidentified active ingredients, what statisticians refer to as stochastic explanatory variables, may create statistical problems such as biased and inefficient inferences. Our current statistical inferences presented in this report are quite safe from those problems. Also, the sale of ELEOTIN as a drug with clear therapeutic claims will not be possible until Eastwood solves this active ingredient identification.

 

This active ingredient problem is common to most of phytopharmaceutical medicines and fortunately people’s attitudes toward these medicines are changing rapidly in recent days. After all, if a certain substance is safe for a long- term use and effective in the treatment of some serious diseases, the practical value of using the substance (without fully knowing what the active ingredients are) is something we should not ignore. There is a trade off between such practical value of using the substance for known efficacy and safety on the one hand, and the prudence of not using it until all the ingredients are fully known. We would like to point out that it is a matter of individual choice within regulatory environments, rather than a matter of scientific rules.

Secondly, because ELEOTIN’s ingredients are all from natural herbs, the uniformity of ELEOTIN’s efficacy is inherently limited. The location and timing of harvest, the conditions of storage after the harvest, etc. contributed to the lack of uniformity. The lack of uniformity adds to the difficulties of forming scientifically acceptable conclusions from the experiments and testimonies.

Thirdly, more often than not, the availability and the quality of a certain herbs are not sufficiently reliable. Some herbs are simply not available sometimes, and some herbs are dangerously contaminated due to the use of pesticides and harmful fertilizers.5 The procurement and the quality control of the material often increase the cost of the production prohibitively, endangering the feasibility of commercialization. By the year-end of 1998, there is going to be an agricultural project in a tropical area where some of the essential herbs for ELEOTIN are going to be grown organically in a controlled environment. This project will provide partial solutions to the problems of limited uniformity and limited bio-availability.

Fourthly, the method of taking ELEOTIN is still quite inconvenient to those people who did not grow up in the tradition of preparing oriental herb mix which invariably involves long hours of brewing. A few researchers argue that making ELEOTIN into a tablet form does, in fact, increase the efficacy, as well as, the convenience of the usage. Eastwood has studied the process of making ELEOTIN into a tablet form. This can be achieved through a spray dry process. However, Eastwood decided not to venture into forming any conclusions regarding the safety and efficacy of tablet form because they have not yet experimented with ELEOTIN in a tablet form long enough.

Fifthly, the analytic studies on ELEOTIN are still in their initial stages. Even though there are positive results defendable at high levels of statistical confidence, Eastwood still requires a huge sample size to procure a comfortable degree of freedom in statistical inference. In other words, when we deal with statistical analysis of such complex diseases as diabetes, we need to have a lot larger size of samples to arrive at the same level of statistical confidence. For now, we feel that these are promising results which warrant a larger scale study. Eastwood is expected to conduct a large scale study on ELEOTIN starting in December 1998.

3.2. Comparison of ELEOTIN with Traditional Hypoglycemic Treatment

We know that there are more than 1000 herbs which are used traditionally in various countries as hypoglycemic agents. However, we believe that ELEOTIN has certain advantages when compared with these traditional hypoglycemic treatments in general.

Firstly, for ELEOTIN there have been systematic studies on what modes of actions are involved both in the working of each individual herb and various combinations thereof, while most traditional hypoglycemic herbs are used just for their alleged overall hypoglycemic effects. The knowledge of the modes of actions allows us to minimize the dosage of ELEOTIN administration while maintaining the efficacy. Also, the same knowledge allows us use of ELEOTIN in conjunction with other therapies such as insulin injection and oral chemical hypoglycemic agents.

We strongly warn the danger of using certain herbs just for their overall and general hypoglycemic effects. Diabetes is a complex disease with many causes and mechanisms. Usage of certain herbs or any other substances for their overall hypoglycemic effects without minimal understanding of specific modes of actions runs the risk of over burdening certain parts of body. For example, when ß-cells are already strained in a severely diabetic patient, usage of herbs that promote insulin secretion will only aggravate the strains on the ß-cells. Knowledge of modes of action is essential for intelligent management and treatment of diabetes.

Secondly, the usage of ELEOTIN has been recorded and analyzed in a statistically systematic manner, while the knowledge of other traditional hypoglycemic herbs are mostly based upon folkloric traditions and oral anecdotes.

Especially, traditional herbs from a highly populated area such as India and China often come with a claim of a large number of satisfied patients. A typical claim is such as “87% of 300,000 patients are cured” etc. Such numbers should not overly impress us because the numbers themselves are seldom confirmable. To the best of our knowledge, as of April 1998, researchers of China and India are still searching for a treatment for diabetes. However, there are sometimes impressive empirical studies regarding some of the traditional herbs.

Thirdly, ELEOTIN is tested to be free of any toxicity or toxic substance, while many traditional herbs are either toxic or dangerously contaminated with pesticides and other harmful substances such as heavy metals. The methodologies of the tests are as follows:

* Standard Plate Count as described in Compendium of Methods for the Microbiological Examination of Foods, 2nd edition, 1984, Chapter 4.51, p66-82

* E. Colit- as described in Petri Firm-AOAC 991.14

* Samonella- as described in Compendium of Analytical Methods, HPB Methods of Microbiological Analysis of Foods 2, MFHPB-  20 September, 1978

* Staphylococcus aureus- as described in Compendium of Analytical Methods, HPB Methods of Microbiological Analysis of Foods, MFHPB-  21 July, 1985

* Yeast and Mold- as described in Standard Methods for Examination of Diary Products, 16th edition, 1992, 8.10, p.281-283.

* Meat Species ID.- as described in CO 16- Elisa-Tek cooked meat inspection kit.

* AA- Metal Analysis in food- as described in AOAC, 15th edition, 1990, 986.15, p.237-273.

* Pesticides- as described in Agricultural Canada, Food Production and Inspection, Laboratory Services Division, L.S.D. P-Pre-023-93(5)-FV, march 1993

The results of the above tests are all certified by proper regulatory agencies of Canada.

It is often claimed if a substances is natural, then it is safe and free from side-effects. Actually, nothing is further from the truth. Of about 1,000 herbs and plants with hypoglycemic effects, at least half are known to have toxicity in one form or another, and only a fraction (less than 5%) are known to be non toxic. Therefore, we should warn that the majority of traditional hypoglycemic treatments are not free of toxicity and side effects.6

However, the comparison of ELEOTIN with traditional hypoglycemic herbs is an evasive issue which does not justify a sweeping conclusion. All the advantages of ELEOTIN with respect to traditional herbs are of rather relative and temporary nature. Knowing that there is a massive amount of research activities being invested in the studies of traditional herbs these days, we can not exclude the possibility that these studies may produce, sooner or later, a herb or some combinations of herbs which provide a better treatment for diabetes than ELEOTIN.

The Therapeutics Of ELEOTIN : 2.0. Experiments on ELEOTIN’s Effects on Diabetes [1]

2.1. Background

2.1.1. Eastwood Bio-Medical Research Inc.

Eastwood Bio-Medical Research Inc. (Eastwood) is a privately owned Canadian company engaged in the development and commercialization of a safe and effective treatment for non-insulin dependent diabetes mellitus (NIDDM).

Eastwood’s core technology, P-700 was originally discovered by one of the most highly respected scientists involved in diabetes research, and experts at various universities such as Yale University, University of Calgary and National Institute of Health. They have invested more than ten years screening various plant extracts to discover a suitable natural composition that provides a safe long-term solution for diabetes. P-700 was discovered following numerous experiments and modifications.

Using that technology, Eastwood developed ELEOTIN, a complex proprietary blend of herbs that helps general health promotion, as a dietary supplement.

2.1.2. ELEOTIN

Several years ago, as an unintended by-product from other research projects whose main targets were to find a clue to the anti-ageing substance from natural sources, an initial herbal combination that was effective in regulating blood glucose levels in diabetic animals was discovered. However, the control of blood glucose levels by this first herbal compound was not sufficient to normalize it, even though blood glucose levels after treatment with this first composition are statistically lower than that of untreated groups. Also, it was not determined whether this first composition had any lasting effects on blood glucose levels following the termination of the treatment. The original findings showed an impressive hypoglycemic compound. However, in order to use the substance for a long-term treatment of diabetes, Eastwood had to make numerous improvements and modifications upon this original combination.

The improvements and modifications resulted from the following work:

1) Literature search which produced candidate plants and plant parts,

2) Screening the candidate plants found in 1) through animal tests to find plants with tangible hypoglycemic efficacy and reliable non-toxicity,

3) A second screening of the candidate plants of step 2) with further animal tests to find a narrower list of plants which helped establish possible modes of actions for their hypoglycemic effects,

4) Trying different combinations of the plants which withstood the above screenings,

5) The compassionate human trials, and collection of testimonies,

6) And finally, small-scale systematic clinical trial.

What should be emphasized here as a noteworthy characteristic of the modification process is that all the above steps took place in an interactive fashion, and more than 700 different combinations of different plants have been tested so far.

The followings are some of the herbs contained in ELEOTIN: Platycodi Radix, Schizandrae Fructus, Capsella Bursa, Astragalus Membranaceus Bunge, Nycium Chinese, Dioscorea Japonica Thunberg, Acanthopanax Sessiliflorum SEEMAN.


2.2. Summary of Experiment Results

In what follows, we provide some summaries of various test results in which a current version of ELEOTIN was used. At first, we will review the results of human testing and later animal testing.

Human Test Results

2.2.1. ELEOTIN Controls Blood Glucose Level in Diabetes Patients

ELEOTIN was administered to diabetes patients. The duration of treatment varied from 3 to 8 months. One result of these experiments is presented in Table 1.

Table 1. Effect of ELEOTIN on the Control of Blood Glucose in Diabetes Patients

 

* BGL = Blood Glucose Level

 

(Additional human tests have been conducted, information available upon your request)
In general, the blood glucose level of all diabetes patients to whom ELEOTIN was administered was lowered over the course of the treatment period.

In various follow-up tests performed in later days, the results are all consistent with the results reported above. However, great variation exists in blood glucose levels among these patients. For example, some patients (~30%) exhibited close to normal blood glucose levels (non-fasting blood glucose level of 120-140 mg/dl). Other patients (~40%) exhibited slightly higher than normal blood glucose levels (non-fasting blood glucose level of 146-178 mg/dl). The remaining patients (~30%) exhibited slightly higher blood glucose levels than all of the other patients (non-fasting blood glucose level of 187-240 mg/dl).

Diet, exercise, and stress, as well as genetic, environmental, and psychological factors, may offer possible explanations for the variation. Differences in the genetic makeup among these patients result in different physiological conditions at the cellular and molecular llevels such as different rates of insulin/receptor up-regulation and different levels of insulin secretion, insulin synthesis, and GLUT2 protein synthesis. Environmental factors, diet, exercise, and stress may be different among diabetes patients. The psychological make-up of the patient (e.g. an individual’s ability to deal with stress) is another important factor when examining the varied responses of diabetes patients to ELEOTIN.

It is noteworthy that some of the patients still have to rely on insulin treatment. Another interesting finding is that even after a few months of the ELEOTIN treatment and in spite of a remarkable reduction of blood glucose levels in all the patients, the blood glucose level of any patient did not go below 128 mg/dl.

Other findings from Eleotin’s Human test results show:

1) Alcohol consumption of any amount reduces the effect of ELEOTIN substantially. In one case, a patient who had suffered serious diabetes for a long time began to show remarkable improvement in all the symptoms related to diabetes after a month of ELEOTIN administration. His blood glucose level approached the normal level, and he was experiencing the improvement of general health.

However, as he resumed the alcoholic consumption from the end of the second month of ELEOTIN use, his blood glucose level reverted to where it was. Subsequently, the patient dropped out of the trial.

In another case, a young patient whose diabetes was recently onset did not stop the alcoholic consumption when he started ELEOTIN usage. The patient did not experience any improvement in the control of blood glucose level within two months. Subsequently, the patient dropped out of the trial. So far Eastwood, at the present time, does not have any systematic studies on the effect of alcohol on the workings of ELEOTIN. The above two cases can be explained by many other factors. Also, the patients could have enjoyed the beneficial effects of ELEOTIN even with their alcohol consumption if they had just stayed a longer period. We report that there were cases where alcohol consumption is negatively correlated with the beneficial effects of ELEOTIN. In any event, consumers taking ELEOTIN should try to minimize their alcohol intake.

2) The age of the patient and the duration of the disease are very important factors that determine the speed of the reduction of blood glucose levels in response to the administration of ELEOTIN. Generally, middle-aged, recent onset cases (6 months to 1year) responded in a few weeks (reaching normal blood glucose levels in a matter of a couple of months) while older patients (over 70) with long histories of diabetes responded as slowly as a year and their blood glucose levels approached the normal levels within two years.

Regardless of the variation among diabetes patients in blood glucose level responses to ELEOTIN, the patients indicated that there was a substantial improvement in many of the general symptoms associated with diabetes. The improvements mentioned by these patients are as follows:

1) An increased amount of urine and reduced frequency of urination resulted.

2) Kidney discomfort, as a result of poor kidney function, is improved, resulting in greater comfort.

3) Interrupted sleep becomes sound.

4) Almost complete relief of pain and stiffness in joints took place.

5) General weakness and fatigue are replaced with an energetic physical condition.

6) Rough skin becomes smooth and soft.

In relation to the improvement of general health, it is noteworthy to mention that the flavonoids and vitamins in ELEOTIN seem to enhance the T cell levels boosting the immune system remarkably, thus helping the users better fight the infections frequently inflicted on diabetic patients.

Interestingly, all the patients felt the improvement of general health conditions before the blood glucose levels actually fell substantially. We interpret this as a consequence of Eleotin’s combinatorial approach, which involves multiple modes of actions which will be explained in later sections. However, we also note a danger that patients who are not monitoring their diabetes closely may have an unjustified sense of “having gotten well”, too prematurely, resulting in premature discontinuance, or negligence of necessary diabetic treatment. In any way, the testimonies of general health promotion are prevalent and consistent. We find it psychologically invaluable considering the chronic nature of the disease in which patients often get depressed and feel helpless.

One interesting observation is that even though most patients experience substantial lowering of the blood glucose levels, they seldom experience full normalization. In other words, it is likely that after a few months of ELEOTIN treatment, the blood glucose level is going to stay slightly higher than the normal level. In contrast, the animals’ blood glucose levels were fully normalized. This difference suggests that Eastwood may have to increase the administered dosage.

Another possible interpretation is that the marginal curative effects of ELEOTIN diminish increasingly as the blood glucose levels approach the normal level, because ELEOTIN relies on ‘mild organic signals’ to the body rather than conveying strong chemical signals for its effect. Mild chemical signals conveyed to the body are likely to be responded more receptively, creating a larger marginal curative effect, when the body is in a more serious condition of diabetes. The body may choose to ignore mild curative signals when the body is not in serious condition. The body may find it better off to stay in a blood glucose level slightly higher than to expensing a large effort to push the level to the normal level.

 

2.2.2. ELEOTIN Induces Blood Glucose Level Control Stability in Diabetic Patients

Three months after termination of treatment with ELEOTIN, the blood glucose levels of six out of seven patients did not change dramatically (Table 2). The blood glucose levels of one out of seven patients increased slightly (168mg/dl to 186mg/dl).

Table 2. Blood Glucose Levels of Diabetes Patients after Termination of the ELEOTIN Treatment

* BLG = Blood Glucose Level

 

We find this result especially encouraging. We see some potential of ELEOTIN as a long-term treatment for diabetes, as well as a temporary treatment. Eastwood hypothesizes that the stable normalization of the blood glucose levels after the discontinuation of ELEOTIN treatment relates to the upregulation of insulin receptors and the regeneration of the ß-cells. Eastwood’s beliefs are also supported by the consistent results from the animal tests that are reported later in this report.

 

ANIMAL TEST RESULTS

In order to test the effect of ELEOTIN on diabetes and to ascertain the potential modes of actions of such effects, GK rats were used. The GK rat is considered to be one of the best animal models for diabetes. This model is characterized by impaired-glucose-insulin secretion and peripheral insulin resistance. Insulin secretion stimulated by glucose is markedly impaired in GK rats. Insulin response and sensitivity of glycogen synthesis, lipogenesis and DNA synthesis in hepatocytes from GK rats are markedly reduced as compared to non-diabetic control rats such as Wistar-Furth (WF). In GK rats, the islet structure was disrupted and areas of pronounced fibrosis were observed in the stroma. As the disease progressed, ß-cell degranulation was observed, but lymphocytic infiltration of the islet was not. Diabetic complications, such as neuropathy and nephropathy, were observed in biochemically and morphologically.

Treatment of animals with ELEOTIN? results in lower levels of blood glucose and following termination of treatment these blood glucose levels remain low. A period of time effective in treating diabetes may be defined as the length of time of treatment that is required to reduce, and possibly stabilize blood glucose levels. Such a period of time may vary from about 1 to 20 months, more preferably this time could be from about 3 to 10 months.

 

2.2.3. ELEOTIN Reverses and Prevents Diabetes in Animals

The treatment of diabetic animals with ELEOTIN resulted in a significant decrease in the level of blood glucose and the incidence of diabetes when compared to PBS-treated animals (Table 3, Figure 3A, 3B).

Table 3. Effect of ELEOTIN on GK Rats

 

*BGL = Bloog Glucose Level
Mean non-fasting blood glucose levels of normal (non-diabetic) Wistar Furth rats, aged 3 months to 7 months, is 145+-17 mg/dl. Any GK rats with a blood glucose level of 230 mg/dl, 5 SD above the mean, were considered diabetic. Rats were treated at 12 weeks of age. Each group contains 20 animals.

It is apparent that ELEOTIN improves the control of blood glucose, resulting in the treatment of diabetes. When diabetic GK rats were treated with ELEOTIN for approximately 4-5 months, the level of blood glucose of 35-50% of GK rats dropped to the normal range when compared to PBS-treated animals. All PBS-untreated animals remained hyperglycaemic. Furthermore, when GK rats were treated with ELEOTIN for approximately 7 months, most of the animals (85%) exhibited normal glycemia, while all untreated animals remained hyperglycaemic. The blood glucose level of ELEOTIN-treated GK rats was lowered to 146 mg/dl (Table 3).

Normalization and Stabilization of Blood Glucose Levels

Following treatment of GK rats with ELEOTIN for 7 months (Table 4), treatment was terminated and blood glucose levels were monitored for a further 3 months. As Table 4 indicates, after treatment was terminated, symptoms did not return for the duration of the study (3 months).

Table 4. Effect of ELEOTIN on the Control of Blood Glucose Levels of GK Rats after Termination of Treatment

Prevention of Diabetes

Table 5 provides data concerning the prevention of diabetes in GK rats. GK rats usually develop diabetes at 6 to 8 weeks of age. In this experiment, treatment of the GK rats with ELEOTIN (as indicated above) began at 3 weeks of age: before the onset of diabetes. As their blood glucose levels indicate, these animals did not develop diabetes and their blood glucose levels remain in the normal blood glucose range for the duration of the study. In the same study, PBS-treated GK rats exhibited very high blood glucose levels and developed diabetes. Thus ELEOTIN prevented the onset of diabetes.

Table 5 Effect of ELEOTIN on the Prevention of Diabetes in GK rates

*BGL = Blood Glucose Level

 

On the basis of blood glucose levels, ELEOTIN prevents diabetes in GK rats when compared to PBS-treated GK rats. As Table 5 indicates, the blood glucose levels of ELEOTIN-treated GK rats are well within the normal range.

In summary, these results demonstrate that ELEOTIN is effective in treating (Table 3), stabilizing (Table 4), and preventing (Table 5) diabetes in animals. The results are consistent with and strongly supportive of the hypotheses of sections 2.2.1, 2.2.2, where similar indications are reported in human cases.

In order to determine the mechanisms involved in the lowering of the blood glucose level in diabetic animals, Eastwood examined insulin receptors present on hepatocytes and skeletal muscles, the secretion of insulin in the pancreatic ß-cells, and the inhibition of alpha-glucohydrolase catalysed enzymatic reactions, which prevents the degradation of complex carbohydrates to monosaccharides.

 

2.2.4. ELEOTIN Upregulates the Insulin Receptors in Animals

Decreased insulin-stimulated glucose uptake is characteristic of insulin resistance. The mechanisms involved in insulin resistance in diabetes is unclear but may involve reduced insulin receptor numbers (secondary to hyperinsulinemia and hyperglycemia), reduced tyrosine kinase activity of the insulin receptor, abnormalities distal to the receptor, and defects in the glucose transport system. Glucose transport activity in diabetes is decreased in both adipocytes and muscle.

To determine the effect ELEOTIN has on the expression of insulin receptors, Eastwood measured the rate at which insulin binds to receptors in ELEOTIN-treated GK rats. Briefly, insulin receptors were purified from control and ELEOTIN-treated GK rats using wheat germ agglutinin (WGA) agarose (Klein et al 1986; Burant et al 1986; Vankatesan et al 1991). The rate at which insulin binds to solubilized receptors was determined using 125I-labelled insulin.

The rate at which insulin binds to partially purified insulin receptors from hepatocytes and muscles significantly increased in the ELEOTIN-treated group when compared to the PBS-treated control group (Tables 6A, 6B, Figures 6A, 6B). This difference is strongly suggestive of the up-regulation of insulin receptors in the presence of ELEOTIN. The rate at which insulin binds to the receptors from hepatocytes is greater than the rate at which insulin binds to skeletal muscle receptors.

These results indicate that ELEOTIN may enhance the expression of insulin receptors better in the liver. Eastwood has not yet formed any hypothesis regarding the differentiated upregulation between the receptors from hepatocytes and skeletal muscle receptors. However, Eastwood believes that this is not unrelated to some patients’ testimonies of improved liver conditions after ELEOTIN treatment. Also, there was a case in which a patient with serious sclerosis for whom ELEOTIN did not produce speedy glucose-lowering effects. At this moment, Eastwood believes that the liver plays an important role in the working of ELEOTIN.

Obviously, the effects of ELEOTIN in the upregulation of insulin receptors have significant therapeutic implications:

1) The upregulation of insulin receptors prevents hypoglycemia occasionally caused by excessive insulin secretion stimulated by such hypoglycemic agents as a sulfonylurea.

2) Also, those people who have used insulin injection to control their blood glucose often experience that their needed effective dosage increases over time and the fluctuation of blood glucose levels increases its width. For those people, the upregulation of insulin receptors is significantly helpful to dampen the fluctuation of the blood glucose level and increase the therapeutic effectiveness of the insulin injection.

3) Testimonies of “feeling better”, and ” feeling more energetic” in response to ELEOTIN treatment seems to be a result of this upregulation of insulin receptors.

4) It is shown also that the blood glucose levels of ELEOTIN treated patients stayed normalized after the termination of ELEOTIN treatment. Eastwood attributes this post-treatment normalization to the upregulation of insulin receptors, as well as other causes.

TABLE 6A, FIGURE 6A

Show the rate of attachment of insulin to receptors obtained from the partially purified liver of PBS-treated GK rats and ELEOTIN extract-treated GK rats. Data represents the mean of 10 animals/group.

TABLE 6A

TABLE 6B

Show the rate at which insulin binds to receptors from partially purified skeletal muscle of the hind limb of PBS-treated GK rats and ELEOTIN extract-treated GK rats. Data represents the mean of 10 animals/group.

2.2.5. ELEOTIN Increases the Secretion of Insulin in Animals

In addition to the measurement of insulin receptors of hepatocytes and skeletal muscle, the level of insulin secretion in the pancreas was measured.

In lean, normal, non-diabetic persons, glucose levels are maintained by a balance between insulin secretion from pancreatic ß-cells and insulin action in the splanchnic (liver and gut) and peripheral (muscle and adipose) tissues. Diabetes develops when this balance is upset and impaired ß-cell function (decrease of insulin secretion), and/or abnormal insulin action (insulin resistance) occurs (Leahy et al 1990; Porte 1991; Reaven 1988). Therefore, the decrease of insulin secretion from the pancreatic ß-cells is one of the mechanisms involved in the development of diabetes. In the future, Eastwood will investigate into how ELEOTIN expresses itself in relation with the insulin secretion. For that purpose, PBS-treated or ELEOTIN-treated GK rats were anesthetized with phenobarbital. The pancreas was isolated and perfused as described in the references below. The perfusate (Krebs-Ringer bicarbonate buffer:118 Mn NaCl, 4 Mn Kcl, 2.5 Mn CaCl2, 1.2 Mn MgSO4, 1.2 Mn KH2PO4 25 Mn NaHCO3, 1.2 g/L bovine serum albumin, and 40 g/L dextran) containing 16 Mn glucose was used. The effluent was collected from the cannula in the portal vein at 2 minutes intervals and stored at -20 C. Insulin secretion was measured and calculated as described in Portha et al (1991) and Giriox et al (1983).

The results, as shown in Table 7 and Figure 7 demonstrate that the secretion of insulin from ELEOTIN-treated GK rats increased when compared to PBS-treated control GK rats. This data indicates that ELEOTIN enhances the secretion of insulin from pancreatic ß-cells as a result of an increase in the synthesis of insulin in the pancreatic ß-cells, and/or an acceleration of insulin secretion.

TABLE 7, FIGURE 7

Show the secretion of insulin in response to glucose from the perfused pancreas of PBS-treated GK rats and ELEOTIN extract-treated GK rats.

 

TABLE 7

2.2.6. ELEOTIN Inhibits alpha-glucohydrolase Breakdown in Animals

Complex carbohydrates present in the diet must be degraded to monosaccharides by alpha-glucohydrolase before they are absorbed in the gastrointestinal tract. In diabetes patients there is less biologically active insulin that utilizes absorbable glucose. Therefore, if the degradation of complex carbohydrates into monosaccharides is inhibited, the amount of absorbable glucose is significantly less, resulting in the requirement for insulin to decrease.

Analysing the inhibition of the degradation of complex carbohydrates into monosaccharides by alpha-glucohydrolase catalysed enzymatic reactions in ELEOTIN treated animals is an essential step to determine the helpfulness of ELEOTIN as a hypoglycaemic agent.

Thus, PBS-treated and ELEOTIN-treated WF rats were fasted overnight and heat-hydrolyzed starch (2g/kg) suspended in water (2g/20ml) was intubated. Fifty minutes later, blood samples were collected and blood glucose levels were determined.

Table 8 and Figure 8 represents the blood glucose level of WF rats administered PBS, PBS and starch, or ELEOTIN and starch. WF rats administered PBS exhibited the lowest blood glucose levels. WF rats administered PBS and starch exhibited the highest blood glucose levels. WF rats administered ELEOTIN and starch exhibited blood glucose levels that were lower than the levels found in WF rats administered PBS and starch, but higher than the levels found in WF rats administered PBS.
 

TABLE 8, FIGURE 8

Show the effect of ELEOTIN extract on blood glucose from oral loads of carbohydrates in normal WF rats.

 

 
Blood Glucose (mg/dl)

 

PBS
82.5
PBS + Starch
130
ELEOTIN + Starch
95

 

These results suggest that the degradation of complex carbohydrate is inhibited because the blood glucose levels of WF rats loaded with carbohydrates (starch) and treated with ELEOTIN were lower than WF rats treated with PBS and loaded with carbohydrates. Because both insulin secretion and insulin action are normal in WF rats, the lower blood glucose level of ELEOTIN-treated rats must have resulted from a lower rate of degradation of complex carbohydrates to monosaccharides, resulting in a decrease of absorbable glucose. Since alpha-glucohydrolase is required for the degradation of complex carbohydrates to monosaccharides, this enzyme must be decreased in ELEOTIN-treated WF rats. In other words, the degradation of starch was inhibited in ELEOTIN-treated WF rats, suggesting that intestinal alpha-glucohydrolase significantly decreased in ELEOTIN-treated WF rats when compared to PBS-treated WF rats.

2.2.7. ELEOTIN Increases the Glucose Transporter in Animals

Glucose enters the ß-cells through a membrane-bound facilitated transporter that is designated GLUT2, or the liver ß-cell transporter. It has been proposed that impaired glucose entry into ß-cells causes a loss of glucose-induced insulin secretion in diabetes patients. This hypothesis is based on the observation that every hyperglycaemic rodent model exhibits a marked reduction of GLUT2 protein in their ß-cells.

To determine whether the level of GLUT2 protein in the pancreatic ß-cells increases in ELEOTIN-treated animals, a Western blot was performed with pancreatic islet homogenates from ELEOTIN-treated GK rats and PBS-treated control GK rats. Preliminary experimental data reveal that ELEOTIN-treated GK rats show an increased level of GLUT2 protein in the pancreatic ß-cells when compared to PBS-treated control GK rats. This result suggests that ELEOTIN may improve glucose transport by increasing the level of transporter protein.

 

2.2.8. Advantages of Combinatorial Approach

The combinatorial approach with a few modes of actions has a few definite advantages, compared with single mode of action approach.

Firstly, the therapeutic burden on a particular mode is relatively light for the same therapeutic result. Thus, the strain of the therapy on a particular organ, such as kidney and liver, can be lightened by choosing this combinatorial approach.

Secondly, there seem to be certain synergistic effects among these different modes of actions when they are set to work simultaneously. Both quantitative and qualitative results suggest that the combinatorial effect of ELEOTIN is definitely superior to the sum of the effects of individual ingredient. In other words, let’s say herb A has a known mode of action I, and herb B has a known mode of action I, too. Roughly speaking, better therapeutic results are observed when a mixture of half dosages of A and B is used than when either of full dosages of A or B is used. Eastwood believes that slightly different chemical structures of complex compounds help the body to lower its resistance to the therapeutically beneficial substance.

However, we present the above result very carefully because in the course of the modifications of previous versions of ELEOTIN Eastwood also found that some combinations can actually synergistically increase the potential toxicity of each component without increasing the beneficial effects of ELEOTIN. In other words, some combinations may work adversely when mixed together. Eastwood has yet to identify a suitable mechanism of interactions which fully explains these evasive observations. At this moment, Eastwood is satisfied with the discovery of a synergistically superior combination. See the chart below.

2.3. Other Trials and Experiments

2.3.1. Toxicity Test of ELEOTIN in Animals

ELEOTIN appears to be safe for long-term use. It is a herbal combination and all of its ingredients have been used for many thousand years in various countries. And they are recorded as safe in various pharmacopoeia and food codes. For example, all the ingredients of ELEOTIN described in section 2.1.2. are items usable as food ingredient according to the food codes of Korea, China, Japan, and most of other south-east Asian countries. Also, the pharmacopia of a few European countries such as the Netherland show most of the ingredients as safe. For US and Canada, all the ingredients are importable, thus usable as drug and food. The usage of the ingredients has been properly reported to and approved by the food and drug-related regulatory bodies. In order to confirm the safety, a toxicity test with animals was performed as below.

WF rats or SJL/J mice were administered the ELEOTIN extract (50 mg/g body weight i.e., 10x’s the regular dose) every day for seven months. Each animal was sacrificed by CO2 asphyxiation. The esophagus, stomach, intestine, lung, heart, kidney, liver, brain and pancreas of each animal was removed. A small piece of each organ was fixed with formalin and stained with hematoxylin and eosin as described elsewhere (Baek, H.S., and Yoon, J.W. (1990). The stained sections were examined under a microscope (Figure 9).

Esophagus, Stomach, and Intestine: The esophagus (Figure 9A), stomach (Figure 9B) and intestine (Figure 9C) showed intact mucosae and lacked inflammatory cell infiltrates or other features of cellular injury or necrosis.

Liver: The liver (Figure 9D) showed well-defined lobules and cords of hepatocytes separated by anastomosing sinuses and central vein, with no mononuclear cell infiltration, necrosis, or intranuclear glycogen infiltration.

Kidney: The kidney (Figure 9E) showed intact glomeruli, tubules, and vessels. Glomerular changes, tubular strophy, interstitial lymphocytic infiltration, and necrosis were not observed.

Lung: A few dispersed macrophages and normal appearing alveoli, bronchioles, bronchi, and vessels were present in the lungs (Figure 9F).

Heart: The endocardium and myocardium of the heart (Figure 9G) were normal.

Brain: Nerve and glial cells of the cerebral cortex (Figure 9H) exhibited no evidence of necrosis, hemorrhage or infarction.

Pancreas: Endocrine and exocrine cells exhibited intact morphology. No necrosis or lymphocytic infiltration was evident.

The data above indicate that even very high doses of ELEOTIN administered over an extended period of time did not have any deleterious effects on these organs.

 

Shows the histological profile of the following tissues from WF rats: Figure 9A Esophagus; Figure 9B Stomach; Figure 9C Intestine; Figure 9D Liver, Figure 9E Kidney, Figure 9F Lung; Figure 9G Heart; Figure 9H Cerebral Cortex (x250), after 7 months treatment with 10x’s the regular dose of ELEOTIN.

2.3.2 Further Studies: Implications on Type I

ELEOTIN not only stimulates ß-cells to secrete insulin but also it seems to assist ß-cells regenerate themselves.

Sulfonylurea agents, taken by more than half of the diabetic population, also promote insulin secretion. However, they function only when ß-cells synthesize insulin. And it is reported that they often result in an inadequate amount of insulin secretion by putting strain on the cells.

In contrast, ELEOTIN seems to help insulin secretion and regeneration of ß-cells through general health promotion.

Eastwood has tried ELEOTIN on a few type I patients. They also reported some improvement in control of blood glucose level as a result of ELEOTIN treatment. Eastwood hypothetically attributes such improvement to the aforementioned regeneration of ß-cells.

The Therapeutics Of ELEOTIN : 1.0 What is diabetes?

1.1. TYPE I (IDDM)

There are two major types of diabetes, Type I and Type II.

Type I, known as insulin-dependent diabetes mellitus (IDDM), is considered an autoimmune disease because the pancreatic cells that produce insulin, the ß-cells, are destroyed by the body’s own immune system. The pancreas then produces little or no insulin. To live, the person with IDDM needs daily injections of insulin. At present, scientists do not know exactly what causes the body’s immune system to attack the ß-cells, but they believe that both genetic factors and viruses may be involved (see reference 2). IDDM accounts for approximately 10 % of diagnosed diabetes in the United States.

IDDM usually develops in children or young adults, although the disorder can appear at any age. Symptoms of IDDM usually develop over a short period, although ß-cell destruction can begin months, or even years, earlier. Symptoms include increased thirst and urination, constant hunger, weight loss, blurred vision, and great tiredness. If not diagnosed and treated with insulin, the person can lapse into a life-threatening coma.

1.2. TYPE II (NIDDM)

Type II diabetes, also known as non-insulin-dependent diabetes mellitus (NIDDM), is much more common than Type I diabetes, affecting 80-90% of all persons with diabetes. (Thus, we use ‘diabetes’ and ‘NIDDM’ interchangeably unless there is a need to differentiate them clearly.) Initially, NIDDM is often of gradual onset in middle age. However, later stages of this disease are very severe, resulting in various long-term complications, such as kidney disease, heart disease, eye disease, nerve disease, and others. These complications make diabetes a leading cause of death.

The symptoms of NIDDM can be vague to diagnose. The symptoms may include fatigue, nausea, frequent urination (particularly at night), and unusual thirst. Frequent urination is one way the body gets rid of excess glucose, and this loss of fluid leads to thirst.

Obesity is an important factor in NIDDM. Also, NIDDM develops more often in genetically predisposed individuals.

The pathological changes in the pancreatic islets of patients with NIDDM are not always apparent. Many patients with NIDDM have normal to high plasma insulin levels. In these individuals, diabetes arises not from a shortage of insulin but may arise from defects in the molecular machinery that mediates the action of insulin on its target cells.

In other words, NIDDM is not caused by ß-cell destruction but by other mechanisms, such as insulin resistance (see reference 3), related to downregulation of insulin receptors, defects in insulin secretion from the pancreatic ß-cells and other changes to the glucose transporter system.

1.3. COST AND TREATMENT OPTIONS

Diabetes, especially NIDDM, also has an enormous financial impact on society. In the U.S., the total economic cost of diabetes (comprised of medical care and lost productivity) was estimated to be $92 billion in 1992. The American Diabetes Association estimated the direct medical costs of diabetes at $45.2 billion. That included the cost of blood-sugar tests and insulin as well as the costs related to kidney failure, retinopathy and other diabetes-related illnesses. The American Diabetes Association also said the indirect costs of diabetes, such as lost productivity and premature death, equal $46.6 billion. World estimates would place the total economic cost of NIDDM conservatively at over 1 trillion dollars.

Presently, no oral hypoglycaemic agent or combination drug therapy exists to treat NIDDM patients without toxicity or side effects. Insulin treatment also provides symptomatic relief rather than a cure. When treatment with insulin is stopped in patients with severe NIDDM, blood glucose levels increase.

It means that most of the current options provide symptomatic or temporary treatment rather than a permanent solution. The void within the art of diabetic treatments in the prevention and/or long-term cure of diabetes has not yet been filled.

1.4. ELEOTIN: PROMISING NEW TREATMENT FOR DIABETES

This report investigates some preliminary but very promising results about a substance called ELEOTIN. ELEOTIN shows a few attributes that establish itself as a strong candidate for a long-term solution to diabetes and its complications. Let us repeat that the tests are quite preliminary. But the test results clearly indicate:

* ELEOTIN enhances insulin secretion from pancreatic ß-cells

* ELEOTIN upregulates insulin receptors leading to an increase in insulin binding

* ELEOTIN inhibits the breakdown of complex carbohydrates into monosaccharides

* ELEOTIN increases the glucose transporter (GLUT2) expression in ß-cells

In addition, ELEOTIN does not have any known side effects, toxicity, and does not develop any resistance.

The Therapeutics Of ELEOTIN In The Treatment Of Non-insulin Dependent Diabetes Mellitus (NIDDM)

A report to inform diabetics and health care professionals of recent studies showing the therapeutic values of a herbal product developed in Canada for the treatment of non-insulin dependent diabetes mellitus (NIDDM). This report brings evidence to the diabetic and the professional health care practitioner that there is an effective non-toxic treatment for NIDDM, without side effects, that often results in a cure for the patient.

Published By:
U.S. Research Reports, Inc.

Post Office Box 7802
Metairie, LA. 70010
Introduction This report is intended to inform diabetics and healthcare professionals of a recent study showing the therapeutic values of a herbal product developed in Canada for the treatment of non-insulin dependent diabetes mellitus (NIDDM).In addition to the most advanced drugs used in the treatment of NIDDM, there are reported to be more than 2,000 herbs that have the ability to lower sugar levels in the blood. However, many of these are toxic and have side effects and none of these are reported to have the effectiveness or cure rates achieved with the ELEOTIN herbal treatment studied in this report. In addition, as shown in this report, the current treatment of NIDDM with drugs has both toxicity and adverse side effects.As this report points out, NIDDM, unlike Type I diabetes where there is no insulin production by the pancreatic ß -cells, is not always caused by low levels of plasma insulin. Many patients with NIDDM have normal to high levels of insulin in the blood. In these cases, diabetes is not caused by a shortage of insulin, but maybe the results of defects in the molecular machinery that mediates the action of insulin on its target cells. In other words, NIDDM is not always caused by the destruction of ß-cells in the pancreas but by other mechanisms, such as insulin resistance, related to down-regulation of insulin receptors, defects in insulin secretion from the pancreatic ß -cells and other changes to the glucose transporter system. In these regards, one of the most important benefits of the ELEOTIN therapy is its effectiveness in those diabetic cases involving insulin resistance, which is the condition described as follows:The pancreas usually continues to produce some insulin in people with NIDDM. However, the insulin fails to limit the level of glucose in the blood. When insulin is present in the blood but the blood fails to maintain a normal level of glucose, the condition is called “insulin resistance.” Insulin resistance is an important factor in NIDDM. A defect in the insulin receptors on the surface of cells may cause insulin resistance. In some cases there may not be a sufficient number of receptors on the cells for insulin or defects in the receptors may prevent insulin from binding to the cells. Insulin resistance may also involve the step after insulin binds with the insulin receptor. For example, insulin may bind to the receptor but the next step that should take place inside the cell does not occur and the cells do not perform their glucose-controlling task.More often than not, the diabetic medicines of today become ineffective over time and the treated patient’s health condition seriously deteriorates and often results in blindness, heart disease, amputations and death. Most current options of treatment provide symptomatic or temporary treatment rather than long-term permanent solutions. ELEOTIN is a candidate for a long-term solution to diabetes and its complications.This report brings evidence to the diabetic and the professional health care practitioner that there is an effective treatment for NIDDM and it often results in a cure for the patient. Extensive research on over 800 herbs, and combinations thereof, by some of the world’s most prominent physicians in the field of diabetes has produced this non-toxic therapy. It is a shining star in the darkness that has surrounded diabetes for centuries.Reports of successful treatment and cures of NIDDM are being received daily as this report is being readied for publication and therefore supplemental reports and clinical studies will be published on this subject in the future.The information in this report has not been reviewed by any regulatory body such as the FDA and is not intended to replace instructions by physicians.U.S. RESEARCH REPORTS, INC.

ELEOTIN: Promising New Treatment for Diabetes 1
Diabetes mellitus (hereinafter, diabetes) is a growing public health problem in both developed and developing countries. A recent World Health Organisation report estimated that more than 100 million people worldwide will suffer from diabetes by the end of this century.

Over 16 million people in the United States have diabetes, a serious life-long disorder. Almost half of these people do not know they have diabetes and are not under medical care. Each year, 500,000 to 700,000 people are diagnosed with diabetes in the United States.